Clinical trial register · United States · industry-sponsored

Clinical Trials in the USA: Industry-Sponsored Studies

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV

Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9120 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 08 Nov 2026, 03:16 UTC

9120

Studies in scope

industry-sponsored, all four open statuses

4955

Recruiting now

open to new participants

2174

Lead sponsors

across recruiting studies

Top states

California 5303 Florida 4471 Illinois 2484 Georgia 2362 Arizona 2258

Trials in this register

Status

Study

Lead sponsor

Phase

Enrol

US states

Start

Recruiting

Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment

NCT05460507Glioma

DrugRhenium Liposome Treatment

Cerenome

Phase 1

Texas

2024-12-12

Recruiting

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

NCT06463028Endometrial Cancer

DrugsSerabelisib·Sapanisertib·Paclitaxel

Faeth Therapeutics

Phase 2

California, Florida, Maryland, Minnesota, New York, Ohio, Oregon, Pennsylvania

2024-12-12

Recruiting

Voice Analysis to Detect Pulmonary Arterial Pressure Changes in Heart Failure

NCT07443670Heart Failure

Noah Labs

Observational

California

2024-12-12

Recruiting

Study of GalaFLEX LITE™ Scaffold in Treatment of Capsular Contracture After Breast Implant Augmentation

NCT05945329Capsular Contracture Associated With Breast Implant, Capsular Contracture Grade III, Capsular Contracture Grade IV

C. R. Bard

Not applicable

250

Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Louisiana

2024-12-12

Recruiting

A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)

NCT06716606Connective Tissue Diseases

DrugBelimumab

GlaxoSmithKline

Phase 3

514

California, New York, Pennsylvania

2024-12-12

Recruiting

Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

NCT06747858Cystic Fibrosis, CFTR Gene Mutation

Arcturus Therapeutics, Inc.

Phase 2

Arizona, Arkansas, California, District of Columbia, Florida, Illinois, Massachusetts, Missouri

2024-12-12

Active, closed

A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)

NCT06741228Generalized Anxiety Disorder

DrugDT120

Definium Therapeutics US, Inc.

Phase 3

214

Arizona, California, Colorado, Florida, Georgia, Illinois, Massachusetts, New Jersey

2024-12-11

Recruiting

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

NCT05421858Candidemia, Candidiasis, Invasive

DrugsCaspofungin·Fosmanogepix·Fluconazole

Basilea Pharmaceutica

Phase 3

450

Alabama, California, Georgia, Indiana, Kentucky, Maryland, Michigan, Minnesota

2024-12-11

Active, closed

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

NCT06627179Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind, Retinal Disease

Laboratoires Thea

Phase 2

California, Florida, Georgia, Massachusetts, Michigan, Oregon, Pennsylvania, Texas

2024-12-11

Active, closed

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06588855Moderately to Severely Active Ulcerative Colitis

DrugAfimkibart

Hoffmann-La Roche

Phase 3

350

Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana

2024-12-11

Recruiting

A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis

NCT06636656Ulcerative Colitis

Boehringer Ingelheim

Phase 2

Arizona, Colorado, Florida, Illinois, Kansas, New York, North Carolina, Texas

2024-12-11

Active, closed

A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease

NCT06734234Kidney Disease

DrugGSK4771261

GlaxoSmithKline

Phase 1

Minnesota

2024-12-11

Recruiting

Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors

NCT06724016Advanced or Metastatic Solid Tumors

DrugsKeytruda·Pembrolizumab

Hanmi Pharmaceutical Company Limited

Phase 1

292

California, Massachusetts, Michigan

2024-12-11

Recruiting

Detecting Change in Muscle Parameters, Pain, and Function With NMES for TTA

NCT06830876Amputation

Sara Peterson-Snyder

Not applicable

Pennsylvania

2024-12-10

Recruiting

A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)

NCT06630234Gastrointestinal Stromal Tumor (GIST)

Deciphera Pharmaceuticals, LLC

Phase 1/2

120

Arizona, California, Colorado, Florida, Massachusetts, Michigan, Minnesota, New York

2024-12-10

Recruiting

A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

NCT06625593Advanced Solid Tumor

BeOne Medicines

Phase 1

168

California, Connecticut, Minnesota, Texas, Washington, Wisconsin

2024-12-09

Active, closed

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

NCT06691984Metastatic Castration-resistant Prostate Cancer

DrugsXaluritamig·Cabazitaxel·Abiraterone·Enzalutamide

Amgen

Phase 3

707

Alabama, California, Florida, Illinois, Indiana, Kentucky, Massachusetts, Michigan

2024-12-09

Active, closed

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)

NCT06534983Muscle-invasive Urothelial Carcinoma

DrugsAutogene cevumeran·Opdivo·Nivolumab

Hoffmann-La Roche

Phase 2

New Jersey, New York

2024-12-09

Active, closed

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies

NCT06645886Hematologic Malignancies, Adult

DrugsKQB198·Dasatinib

Kumquat Biosciences Inc.

Phase 1

California, Colorado, Florida, Michigan, North Carolina, Ohio, Tennessee, Texas

2024-12-09

Active, closed

A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

NCT06588686Idiopathic Pulmonary Fibrosis (IPF)

Vicore Pharma AB

Phase 2

378

Alabama, California, Colorado, Florida, Georgia, Illinois, Kansas, Michigan

2024-12-09

Active, closed

The JenaValve ALIGN-AR LVAD Registry

NCT06594705Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency, Aortic Valve Disease

JenaValve Technology, Inc.

Not applicable

California, District of Columbia, Georgia, Illinois, Michigan, Minnesota, Missouri, New York

2024-12-09

Recruiting

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

NCT06597019Familial Hypercholesterolemia - Heterozygous

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

California, District of Columbia, Florida, New York, Utah, Virginia, West Virginia

2024-12-09

Recruiting

A Clinical Registry to Demonstrate the Safety and Performance of Teleflex Vascular Access Devices

NCT06604039Vascular Access Device

Teleflex

Observational

2,500

Alabama, California, Massachusetts

2024-12-08

Recruiting

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

NCT06679140COVID-19 SARS-CoV-2 Infection

DrugIbuzatrelvir

Pfizer

Phase 3

2,330

Alabama, Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Idaho

2024-12-08

Active, closed

Post Marketing Study of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers Mixed With Autograft in Patients Undergoing Posterolateral Lumbar Fusion

NCT04679844Degenerative Disc Disease, Spine Fusion, Back Pain

Kuros Biosurgery AG

Not applicable

California, Michigan, Missouri, Pennsylvania, Tennessee, Washington

2024-12-06

Recruiting

Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot and Venous Leg Ulcers.

NCT06826339Venous Leg Ulcer, Venous Leg, Diabetic Foot, Diabetic Foot Ulcer

Tiger Biosciences, LLC.

Phase 4

340

Pennsylvania

2024-12-06

Recruiting

Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients

NCT06706674Irritability Associated With Autism Spectrum Disorder

DrugLumateperone

Intra-Cellular Therapies, Inc.

Phase 3

160

Arkansas, California, Connecticut, Florida, Georgia, Illinois, Indiana, Louisiana

2024-12-06

Recruiting

A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)

NCT06735755Glycogen Storage Disease Type Ia

Beam Therapeutics Inc.

Phase 1/2

California, Connecticut, Texas

2024-12-06

Recruiting

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

NCT06667908Carcinoma, Non-Small-Cell Lung

DrugsJNJ-90301900·Durvalumab

Johnson & Johnson Enterprise Innovation Inc.

Phase 2

130

California, Connecticut, Florida, Georgia, Massachusetts, Missouri, New Jersey, New York

2024-12-06

Recruiting

Amnioinfusion for Fetal Renal Failure

NCT06728228Multicystic Dysplastic Kidney, Polycystic Kidney Disease, Fetal Renal Anomaly, Anhydramnios

Fetal Care Center, PLLC

Not applicable

Texas

2024-12-05

Recruiting

A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

NCT06089616Fibrodysplasia Ossificans Progressiva

Ipsen

Observational

100

California, Pennsylvania

2024-12-05

Recruiting

A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).

NCT06655324Healthy

Merck Sharp & Dohme LLC

Phase 1

250

California, Florida, Missouri, Nebraska, Ohio, Oklahoma, Tennessee

2024-12-05

Active, closed

Phase 2b Open-Label Repeat Kidney Biopsy Study

NCT06740526IgA Nephropathy

DrugSibeprenlimab

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 2

Alabama, California, Colorado, Massachusetts, South Dakota, Texas

2024-12-05

Recruiting

First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

NCT06603844Solid Tumor

Corbus Pharmaceuticals Inc.

Phase 1/2

156

Alabama, Arizona, California, Colorado, Florida, Illinois, Minnesota, Nebraska

2024-12-04

Active, closed

Nipocalimab in Moderate to Severe Sjogren's Disease

NCT06741969Sjogrens Syndrome

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

655

California, Colorado, Florida, Georgia, Illinois, Iowa, Kansas, Michigan

2024-12-04

Recruiting

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma

NCT06768489Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis

DrugsRamantamig·Pomalidomide·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 1

276

Colorado, Georgia

2024-12-04

Active, closed

A Spanish-language Caregiver-Enabled Care Program

NCT06631144Dementia, Dementia Alzheimers, Alzheimer Disease, Caregiver

Ceresti Health, Inc.

Not applicable

270

California

2024-12-04

Recruiting

Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant

NCT06938867E Coli Infections, Allogenic Transplant Patients

SNIPR Biome Aps.

Phase 1/2

California, Maryland, Massachusetts, Minnesota, New York, Pennsylvania, Texas, Washington

2024-12-04

Recruiting

A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis

NCT06454188Psoriatic Arthritis, Spondyloarthritis, Axial

DrugUpadacitinib

CARE ARTHRITIS LTD.

Phase 4

100

Ohio, Oregon, Pennsylvania

2024-12-03

By invitation

A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT06679946Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

DrugVutrisiran

Alnylam Pharmaceuticals

Phase 3

700

Arizona, California, District of Columbia, Illinois, Indiana, Kansas, Maryland, Massachusetts

2024-12-03

Active, closed

A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)

NCT06706622Multiple System Atrophy

DrugAmlenetug

H. Lundbeck A/S

Phase 3

401

Arizona, Arkansas, California, Colorado, Connecticut, Florida, Indiana, Maryland

2024-12-03

Active, closed

A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab

NCT06706817Chronic Rhinosinusitis With Nasal Polyps

AstraZeneca

Phase 3

181

California, Illinois, Massachusetts, Missouri

2024-12-03

Active, closed

A Clinical Study to Evaluate the Efficacy of Activated Silk™ 27P-α in Subjects, Aged 35-65 Years of Age, to Improve the Signs of Aging, by Comparing to a Placebo

NCT06804772Skin Aging

Victoria Collotta

Not applicable

Massachusetts

2024-12-03

Recruiting

Adaptive and Individualized AAC Phase II

NCT06337188Communication Disorders

Altec Inc.

Not applicable

Nebraska

2024-12-03

Active, closed

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)

NCT06685757Antibody-mediated Rejection

DrugFelzartamab

Biogen

Phase 3

132

California, Colorado, Illinois, Kansas, Louisiana, Minnesota, Missouri, Nebraska

2024-12-03

Recruiting

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

NCT06472245Patients With Non-Small Cell Lung Cancer

DrugsTedopi·Docetaxel

OSE Immunotherapeutics

Phase 3

363

California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas, Louisiana

2024-12-03

Active, closed

Clinical Study of a 3D Shaded Zirconia for Chairside CAD/CAM Restorations

NCT06713577Dental Prosthesis Failure, Dental Prosthesis Complication

Dentsply Sirona Implants and Consumables

Observational

Michigan

2024-12-03

Recruiting

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

NCT06717698Chronic Kidney Disease

DrugSemaglutide

Novo Nordisk A/S

Phase 2

465

California, Colorado, Florida, Illinois, Indiana, Michigan, Missouri, New York

2024-12-02

Recruiting

Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels

NCT06496243Dyslipidemias

DrugObicetrapib

NewAmsterdam Pharma

Phase 2

Pennsylvania

2024-12-02

Active, closed

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

NCT06694805HIV Infections

DrugsRpv La·Cabotegravir·B/F/TAF

ViiV Healthcare

Phase 3

326

Alabama, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia

2024-12-02

Active, closed

Comprehensive Assessment of Cancer Theranostic Response

NCT06815354Prostate Cancer

AIQ Solutions

Not applicable

New York, Texas

2024-12-02

Recruiting

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

NCT06667700Coronavirus Disease (COVID-19)

DrugMolnupiravir

Merck Sharp & Dohme LLC

Phase 3

3,082

Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois

2024-12-02

Not yet open

Changes in Amino Acid Absorption After Adding a Probiotic to an Acute Protein Feeding

NCT06701604Amino Acid Absorption, Probiotic

The Archer-Daniels-Midland Company

Not applicable

Texas

2024-12-02

By invitation

A Study to Assess the Impact of a Nutritional Supplement on Wellbeing and Nutrient Absorption

NCT06749808Nutrition Status

Pharmanex

Not applicable

Utah

2024-12-01

Active, closed

A Study of RSLV-132 in Females With Sjögren's Disease

NCT06440525Primary Sjögren Syndrome

Resolve Therapeutics

Phase 2

106

California, Florida, Illinois, Iowa, Massachusetts, New Mexico, North Carolina, Pennsylvania

2024-12-01

Recruiting

Evaluating Cryopreserved Osteochondral Allograft Cores for the Treatment of Osteochondral Lesions in the Knee

NCT06216756Osteochondral Defect

AlloSource

Not applicable

Arizona, California, Illinois, Kentucky

2024-12-01

Active, closed

Retrospective PNS Study

NCT06832449Chronic Pain

Curonix LLC

Observational

200

Colorado

2024-12-01

By invitation

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept

NCT06674577IgA Nephropathy (IgAN), Renal and Urinary Disorders, Berger Disease

DrugAtacicept

Vera Therapeutics, Inc.

Phase 2

750

California

2024-12-01

Not yet open

Understanding Patient Engagement Trends in Anxiety Disorder Clinical Research

NCT06155565Anxiety Disorder

Power Life Sciences Inc.

Observational

500

California

2024-12

Not yet open

Exploring Clinical Study Experiences of People With Post Traumatic Stress Disorder

NCT06146049Post Traumatic Stress Disorder

Power Life Sciences Inc.

Observational

500

California

2024-12

Not yet open

Evaluating the Occurrence of Participation Trends Among Weight Loss Clinical Trials Patients

NCT06155552Weight Loss

Power Life Sciences Inc.

Observational

500

California

2024-12

Not yet open

Insights Into Participating in Clinical Studies for Anorexia

NCT06146075Anorexia

Power Life Sciences Inc.

Observational

500

California

2024-12

Active, closed

Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion

NCT06685848Hematologic Neoplasms

Hemanext

Not applicable

North Carolina

2024-11-29

Active, closed

SakuraBead Used as Resorbable Embolic for Genicular Artery Embolization

NCT06550024Osteo Arthritis Knee, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases

CrannMed

Not applicable

Alabama, California, Florida, North Carolina, Virginia

2024-11-28

Recruiting

A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

NCT06634589B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell Lymphoma

DrugsTacabrutideg·Mosunetuzumab·Sonrotoclax·Glofitamab

BeOne Medicines

Phase 1/2

Arizona, California, Florida, Kansas, Minnesota, Missouri, New York, Pennsylvania

2024-11-27

Recruiting

CoMind Early Feasibility Study

NCT06368648Intracranial Pressure, Intracranial Pressure Changes, Traumatic Brain Injury, Intracerebral Hemorrhage

CoMind Technologies Limited

Observational

581

Arizona, California, Delaware, District of Columbia, Florida, Iowa, Kansas, Missouri

2024-11-27

Active, closed

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration

NCT06495918Neovascular Age-related Macular Degeneration

DrugsOtx-Tki·Aflibercept

Ocular Therapeutix, Inc.

Phase 3

825

Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana

2024-11-27

Recruiting

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)

DrugSurovatamig

AstraZeneca

Phase 2

270

Arizona, California, Florida, Illinois, Iowa, Kansas, Minnesota, Missouri

2024-11-27

Active, closed

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

NCT06428396Metastatic Breast Cancer

DrugsBelzutifan·Exemestane·Everolimus·Fulvestrant

Merck Sharp & Dohme LLC

Phase 2

120

Arizona, California, Georgia, Louisiana, Nevada, New Jersey, Texas, Wisconsin

2024-11-27

Active, closed

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

NCT06683742Wet Age Related Macular Degeneration, wAMD

DrugsEYP-1901·Aflibercept

EyePoint Pharmaceuticals, Inc.

Phase 3

400

Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Kentucky

2024-11-27

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

NCT06627647Non-squamous Non-small Cell Lung Cancer

DrugsRilvegostomig·Pemetrexed·Keytruda·Cisplatin

AstraZeneca

Phase 3

1,160

Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia

2024-11-27

Recruiting

A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age

NCT06693895Chickenpox

DrugsMarketed varicella vaccine·Hepatitis A vaccine·PCV (pneumococcal conjugate vaccine) 13·PCV 20

GlaxoSmithKline

Phase 3

750

Arizona, California, Florida, Illinois, Kansas, Louisiana, Minnesota, Nebraska

2024-11-26

Active, closed

Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine

NCT06543914Migraine

AbbVie

Observational

1,314

Alabama, Arizona, California, Florida, Kentucky, New York, Pennsylvania, Virginia

2024-11-26

Active, closed

Evaluation of the Safety and Effectiveness of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

NCT06498960Normal Pressure Hydrocephalus

CereVasc Inc

Not applicable

230

California, Connecticut, Florida, Illinois, Indiana, Kansas, Kentucky, Massachusetts

2024-11-26

Recruiting

External Trigeminal Nerve Stimulation for Migraine Treatment in Pregnancy

NCT06788977Pregnancy, Migraine, Headache, Postpartum

Cefaly Technology

Observational

550

Connecticut

2024-11-25

Recruiting

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

NCT06651281Crohn Disease, Colitis, Ulcerative

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,380

Connecticut, Michigan, Missouri, New York, Texas, Virginia, Washington

2024-11-25

Active, closed

GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis Post-Approval Study

NCT06578741Abdominal Aortic Aneurysm, Pararenal Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm

W.L.Gore & Associates

Not applicable

310

California

2024-11-25

Active, closed

Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis

NCT06444113Multiple Sclerosis

Novartis Pharmaceuticals

Phase 4

California, Colorado, Illinois, Massachusetts

2024-11-25

By invitation

Control of Assistive Devices Via Brain-Computer Interface Technology

NCT06710626Tetraplegia/Tetraparesis, Amyotrophic Lateral Sclerosis (ALS), Quadriplegia, Spinal Cord Injury (SCI)

Neuralink Corp

Not applicable

Arizona

2024-11-25

Recruiting

Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

NCT06613100Prostate Cancer

DrugXaluritamig

Amgen

Phase 1

California, Missouri, Ohio, Pennsylvania, South Carolina, Washington, Wisconsin

2024-11-25

Recruiting

Evaluating Intact Fish Skin Graft and Standard of Care Versus Standard of Care Alone in Nonhealing Venous Leg Ulcers

NCT06693570Venous Leg Ulcer (VLU), Venous Leg Ulcers, Venous Leg, Nonhealing Venous Leg Ulcer

Kerecis Ltd.

Phase 4

150

Pennsylvania

2024-11-25

Active, closed

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants

NCT06720038Pneumococcal Vaccines

DrugPCV20

Vaxcyte, Inc.

Phase 2

900

Arkansas, California, Colorado, Florida, Idaho, Kentucky, Louisiana, Nebraska

2024-11-25

Active, closed

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

NCT06635824PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC

DrugsDocetaxel·Pembrolizumab

Genmab

Phase 3

191

Arizona, California, Florida, Georgia, Hawaii, Illinois, Indiana, Kentucky

2024-11-25

Recruiting

ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

NCT06597721Advanced Solid Tumor, PDAC, HNSCC

Adcendo ApS

Phase 1

210

Arkansas, Connecticut, Massachusetts, Missouri, New York, Texas

2024-11-25

Recruiting

Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)

NCT06500793Pharmacokinetics, Healthy Volunteer

DrugsPF614·Nafamostat Mesylate

Ensysce Biosciences

Phase 1

Florida

2024-11-24

Recruiting

Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients

NCT06690398Irritability Associated With Autism Spectrum Disorder

DrugLumateperone

Intra-Cellular Therapies, Inc.

Phase 3

160

Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Massachusetts

2024-11-22

Active, closed

A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment

NCT06668805Noonan Syndrome

DrugVosoritide

BioMarin Pharmaceutical

Phase 2

California, Colorado, Delaware, District of Columbia, Florida, Georgia, Illinois, Indiana

2024-11-22

Active, closed

Safety and Effectiveness of the Luna System in People With Type 1 Diabetes Mellitus

NCT06627517Type 1 Diabetes Mellitus, Sleep Quality

Luna Diabetes

Not applicable

120

California, Colorado, Minnesota

2024-11-22

Active, closed

Retrospective Acute Care Appendectomy Study

NCT06624215Acute Appendicitis

Intuitive Surgical

Observational

1,000

Ohio, Oregon, Texas

2024-11-22

Recruiting

Acellular Dermal Matrix Investigation in Breast Reconstruction

NCT06456554Breast Reconstruction

RTI Surgical

Not applicable

467

Arkansas, California, Colorado, Kansas, Missouri, New York, Ohio, Oklahoma

2024-11-22

Recruiting

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

NCT06532006Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer

DrugsHLX22·Trastuzumab·Capecitabine·Oxaliplatin

Shanghai Henlius Biotech

Phase 3

550

California, Colorado, Florida, Illinois, Iowa, Missouri, Nebraska, Nevada

2024-11-22

Active, closed

A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

NCT06693531Eosinophilic Esophagitis (EoE)

DrugDupilumab

Regeneron Pharmaceuticals

Observational

368

Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois

2024-11-22

Recruiting

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

NCT06617325Systemic Lupus Erythematosus

UCB Biopharma SRL

Phase 3

450

Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana

2024-11-21

Active, closed

A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)

NCT06698042Lung Cancer, Non-Small Cell Lung Cancer

Drugs) Berahyaluronidase alfa·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

California, Illinois, New York, Ohio

2024-11-21

Recruiting

Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder

NCT06701903Generalized Anxiety Disorder

DrugITI-1284

Intra-Cellular Therapies, Inc.

Phase 2

570

Alabama, Arkansas, California, Connecticut, Florida, Georgia, Mississippi, New York

2024-11-21

Recruiting

A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

NCT06678659Unresectable, Locally Advanced, Metastatic Cancers, Relapsed/Refractory Lymphomas

Recursion Pharmaceuticals Inc.

Phase 1/2

170

California, Ohio, Tennessee, Utah

2024-11-21

Active, closed

Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA)

NCT06567769Sanfilippo Syndrome Type A

GC Biopharma Corp

Phase 1

California, Minnesota

2024-11-21

Recruiting

Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension

NCT06526858Resistant Hypertension

DeepQure Inc.

Not applicable

California, Florida, Georgia, Michigan, Minnesota

2024-11-21

Recruiting

ORB-021 In Patients With Advanced Solid Tumors

NCT06607939Advanced Solid Tumors Cancer

Orionis Biosciences Inc

Phase 1

Arizona, Texas

2024-11-21

Active, closed

A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration

NCT06660667Neovascular Age-related Macular Degeneration

Sanofi

Phase 1/2

Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Nevada

2024-11-21

Recruiting

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

NCT06458712Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)

Duke Street Bio Ltd

Phase 1

180

California, Connecticut, New York, Texas

2024-11-21

Recruiting

AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor

NCT06699056Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement

Peerbridge Health, Inc

Observational

2,000

California, Michigan, New Jersey, New York, North Carolina, Texas

2024-11-21

Recruiting

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

NCT06619561Chronic Graft-Versus-Host Disease (cGVHD)

DrugVimseltinib

Deciphera Pharmaceuticals, LLC

Phase 2

California, Florida, Georgia, Illinois, Kansas, Kentucky, Massachusetts, Michigan

2024-11-21

Recruiting

A Single-arm, Pivotal Study to Evaluate Acute Device and Technical Success of the CGuard Prime Carotid Stent System When Used in Conjunction to the ENROUTE Transcarotid Neuroprotection System in Patients Undergoing Carotid Artery Stenting Via the Transcarotid Artery Revascularization Approach

NCT06653387Carotid Artery Diseases

InspireMD

Not applicable

California, Indiana, Minnesota, Missouri, Montana, New York, Ohio

2024-11-20

Recruiting

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

NCT06589440Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

DrugsBalstilimab·Botensilimab

Stingray Therapeutics

Phase 2

New Jersey, Texas, Washington

2024-11-20

Active, closed

A Study Assessing KB304 for the Treatment of Wrinkles in Women

NCT06724900Wrinkles in Decolletage, Pigmentation, Décolleté Wrinkles

Krystal Biotech, Inc.

Phase 1/2

California

2024-11-20

Active, closed

Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1

NCT06532656HIV-1-infection

DrugsBixlenvo·Lenacapavir

Gilead Sciences

Phase 2/3

District of Columbia, Florida, Georgia, Illinois

2024-11-20

Active, closed

Avalus Ultra Post-Approval Study (PAS)

NCT06506903Aortic Valve Disease

Medtronic Cardiac Surgery

Not applicable

190

Connecticut, Florida, Georgia, Illinois, Michigan, Minnesota, New York, Ohio

2024-11-20

Recruiting

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

NCT06690775Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer

DrugsTORL-1-23·Pegfilgrastim

TORL Biotherapeutics, LLC

Phase 2

230

Arizona, California, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts

2024-11-20

Recruiting

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

NCT06369285Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer

DrugAlisertib

Puma Biotechnology, Inc.

Phase 2

225

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois

2024-11-19

Recruiting

A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age

NCT06702449Urinary Tract Infections

GlaxoSmithKline

Phase 1/2

448

Kansas, New Jersey, New York, Texas, Washington

2024-11-19

Active, closed

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

NCT06578247Leukemia

DrugQuizartinib

Daiichi Sankyo

Phase 3

700

Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois

2024-11-19

Active, closed

INJECTABLE COLD ENERGY THERAPY FOR THE MANAGEMENT OF CHRONIC PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE

NCT06700109Osteoarthritis (OA) of the Knee

DrugTriamcinolone acetate

Brixton Biosciences, Inc.

Not applicable

263

California, District of Columbia, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland

2024-11-19

Recruiting

A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

NCT06672939Obesity, Overweight

DrugOrforglipron

Eli Lilly and Company

Phase 3

150

California, Connecticut, Georgia, Illinois, Louisiana, Missouri, North Carolina, Pennsylvania

2024-11-18

Active, closed

A Clinical Study to Evaluate the Efficacy of Activated Silk™ 27P-α in Subjects, Aged 35-65 Years of Age, to Improve the Signs of Aging

NCT06804759Skin Aging

Victoria Collotta

Not applicable

Massachusetts

2024-11-18

Active, closed

Stryker Facial iD Universal Plate Configurator: A Retrospective Post Market Follow Up

NCT07245810Mandibular Fractures, Facial Fracture, Maxilla Fracture, Orthognathic Surgical Procedures

Stryker Craniomaxillofacial

Observational

726

New York

2024-11-18

By invitation

A Modified Platform Trial of Multiple CAMPs for the Management of Diabetic Foot Ulcers and Venous Leg Ulcers

NCT06453187Diabetic Foot Ulcer, Venous Leg Ulcer

Integra LifeSciences Corporation

Not applicable

350

California, Connecticut, Florida, Georgia, Illinois, Louisiana, Maryland, New York

2024-11-18

By invitation

Harnessing Digital Medicine to Improve Allergic Rhinitis Management in Primary Care (DMAR)

NCT06603935Allergic Rhinitis, Sinusitis

QHSLab, Inc.

Not applicable

240

Florida

2024-11-18

Recruiting

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors

NCT06752681Advanced or Metastatic Solid Tumors

Day One Biopharmaceuticals, Inc.

Phase 1

300

Connecticut, Florida, Indiana, Michigan, New York, Oklahoma, Tennessee, Texas

2024-11-18

Not yet open

Evaluation of Investigational Hearing Instrument Features

NCT06710236Hearing Loss

Sonova AG

Not applicable

Illinois

2024-11-18

Recruiting

An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer

NCT06693336Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)

DrugPaclitaxel

ToLymph Inc.

Phase 2

Minnesota

2024-11-18

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

NCT06692738Non-small Cell Lung Cancer

DrugsRilvegostomig·Nab-paclitaxel·Keytruda·Paclitaxel

AstraZeneca

Phase 3

1,160

Arizona, Arkansas, California, Connecticut, Delaware, Florida, Georgia, Idaho

2024-11-18

Active, closed

Evaluation of a Simple-Prep Controlled Embolic

NCT06453642Embolization, Vascular Tumor, Renal Angiomyolipoma, Renal Cell Carcinoma

Fluidx Medical Technology, Inc.

Not applicable

114

California, Colorado, Illinois, Indiana, Minnesota, Missouri, New York, North Carolina

2024-11-18

Recruiting

Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease

NCT06605378Chronic Granulomatous Disease (CGD)

Ensoma

Observational

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia

2024-11-18

Recruiting

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

NCT06672549Obesity, Overweight

DrugOrforglipron

Eli Lilly and Company

Phase 3

125

Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana

2024-11-18

Recruiting

Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

NCT06228053Metastatic Castration-resistant Prostate Cancer

DrugsSX-682·Xtandi·Enzalutamide

Syntrix Biosystems, Inc.

Phase 2

California, Michigan, Minnesota, North Carolina, Wisconsin

2024-11-18

Active, closed

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

NCT06465329Non Small Cell Lung Cancer, NSCLC

DrugsMarlotamig·Cemiplimab

Regeneron Pharmaceuticals

Phase 2

184

California, Illinois, Michigan, Ohio, Oregon, Rhode Island, South Dakota, Tennessee

2024-11-18

Recruiting

To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension

NCT06343298Difficult to Control Hypertension

E-Star BioTech, LLC

Phase 2

120

Arkansas, California, Florida, Georgia, Illinois, Michigan, Mississippi, New York

2024-11-17

By invitation

COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable

NCT06763549Cardiopulmonary Failure, Myocardial Infarction (MI), Heart Decompensation, Heart Failure

Peerbridge Health, Inc

Observational

15,000

Florida

2024-11-16

Active, closed

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

NCT06616194Migraine

DrugRimegepant

Pfizer

Phase 3

636

Arizona, California, Colorado, Illinois, Massachusetts, Michigan, Missouri, New Jersey

2024-11-15

Recruiting

AvertD Post-Approval Study

NCT07135323Opioid Use Disorder

Prescient Medicine Holdings, Inc.

Observational

4,000

Indiana

2024-11-15

Recruiting

Evaluation of Pulsed Field Ablation of the Posterior Nasal Nerve for Chronic Rhinitis

NCT06598319Chronic Rhinitis

Aventix Medical Inc.

Not applicable

Colorado, Mississippi, Texas

2024-11-15

Recruiting

Peripheral Bypass Trial for Completion Control

NCT06264843Chronic Limb-Threatening Ischemia

Medistim ASA

Observational

450

California

2024-11-14

Active, closed

A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

NCT06637501Chronic Lymphocytic Leukemia

DrugsSonrotoclax·Zanubrutinib

BeOne Medicines

Phase 2

Florida, Georgia, Illinois, Maryland, Nebraska, Oregon, Texas, Utah

2024-11-14

Recruiting

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

NCT06619587Solid Tumor

Genentech, Inc.

Phase 1

410

California, Colorado, Connecticut, Florida, Illinois, Massachusetts, Michigan, New York

2024-11-14

Recruiting

A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

NCT06422923Epilepsy, Temporal Lobe

DrugNRTX-1001

Neurona Therapeutics

Phase 1/2

Arkansas, California, Colorado, Illinois, Iowa, New York, North Carolina, Oregon

2024-11-14

Recruiting

Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers

NCT06681428Diabetic Foot Ulcer (DFU), Chronic Foot Ulcers

Tides Medical

Not applicable

240

California, Florida, North Carolina, Ohio, Virginia

2024-11-14

Recruiting

Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B

NCT06680232HEPATITIS B CHRONIC

DrugPbgene-Hbv

Precision BioSciences, Inc.

Phase 1

Massachusetts

2024-11-14

Recruiting

First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors

NCT06644755Solid Tumors, Sarcoma

Daiichi Sankyo

Phase 1

150

Massachusetts, New York, Tennessee

2024-11-14

Recruiting

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection

NCT07024641Hepatitis B Virus Infection

GigaGen, Inc.

Phase 1

Arizona, California, Georgia, Iowa, Kansas, Maryland, Texas, Virginia

2024-11-13

Recruiting

Bone Mineral Density Precision Study

NCT06830811Indicated for EOSedge Imaging

Alphatec Spine, Inc.

Not applicable

Indiana

2024-11-13

Recruiting

Delivering Transcutaneous Auricular Neurostimulation to Reduce Blood Loss During Dialysis AV Graft Placement Procedures

NCT06647017Blood Loss, Surgical

University Surgical Vascular

Not applicable

Georgia

2024-11-13

Active, closed

A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia

NCT06859073Healthy Volunteers, Hyperuricemia

Novo Nordisk A/S

Phase 1

California, Maryland

2024-11-13

Recruiting

PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

NCT06607627Generalized Myasthenia Gravis, gMG

Alexion Pharmaceuticals, Inc.

Phase 3

District of Columbia, Virginia

2024-11-13

Active, closed

Phase I/II Study to a Assess the GBS-06 Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age.

NCT06611371Group B Streptococcal Infections

Inventprise Inc.

Phase 1/2

600

New York

2024-11-12

By invitation

Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder

NCT06374264Neuromyelitis Optica Spectrum Disorder

MedRhythms, Inc.

Not applicable

Georgia, Massachusetts

2024-11-12

Recruiting

Safety and Immunogenicity of V540B in Healthy Adults (V540B-002).

NCT06623409Healthy

DrugNonavalent HPV vaccine

Merck Sharp & Dohme LLC

Phase 1

124

California, Florida, Nebraska

2024-11-12

Active, closed

Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study

NCT06654895Sepsis, Septic Shock

Bluejay Diagnostics, Inc.

Observational

700

Florida, Massachusetts, North Carolina, Tennessee, Utah

2024-11-12

Recruiting

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

NCT06632457Metabolic Dysfunction Associated Steatohepatitis

Boehringer Ingelheim

Phase 3

1,590

Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Iowa

2024-11-12

Recruiting

LDGraft in Single Level Anterior Lumbar Interbody Fusion (ALIF)

NCT06462729Degenerative Disc Disease, Lumbar Disc Disease, Spine Disease, Lumbar Spine Degeneration

Locate Bio Pty Ltd

Phase 1/2

Indiana, North Carolina, Tennessee

2024-11-12

Active, closed

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

NCT06537414Chronic Hepatitis B Virus Infection, Hepatitis B

DrugBepirovirsen

GlaxoSmithKline

Phase 2

283

California, Minnesota, New York, Pennsylvania

2024-11-11

Active, closed

A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

NCT06531499Metastatic Castration-Resistant Prostate Cancer

DrugLu-PSMA

Novartis Pharmaceuticals

Phase 1

110

California, Minnesota, Missouri, Nebraska

2024-11-11

Recruiting

A Trial to Test the Safety and Efficacy of TEV-53408 in Participants With Vitiligo

NCT06625177Vitiligo

DrugTEV-53408

Teva Branded Pharmaceutical Products R&D LLC

Phase 1

Arizona, Arkansas, California, Florida, Illinois, Kentucky, Michigan, Oregon

2024-11-11

Active, closed

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

NCT06719141Developmental and Epileptic Encephalopathy

DrugBexicaserin

Longboard Pharmaceuticals

Phase 3

367

Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Idaho, Illinois

2024-11-11

By invitation

Long Term Follow-up Study of AAVAnc80-hOTOF Gene Therapy

NCT06696456Otoferlin Gene-mediated Hearing Loss

Eli Lilly and Company

Observational

Iowa, Massachusetts, Pennsylvania

2024-11-11

Active, closed

Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older

NCT06686654Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization

DrugHMPV vaccine

Sanofi Pasteur, a Sanofi Company

Phase 1/2

1,530

Arizona, California, Colorado, District of Columbia, Florida, Idaho, Kansas, Maryland

2024-11-11

Active, closed

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

NCT06655155Systemic Sclerosis (SSc)

argenx

Phase 2

Arizona, California, Florida, Illinois, Louisiana, Maryland, Michigan, Pennsylvania

2024-11-11

By invitation

Xeltis Hemodialysis Access Graft (aXess) US Study

NCT06494631End Stage Renal Disease

Xeltis

Not applicable

140

Arizona, Florida, Massachusetts, Mississippi, North Carolina, Texas

2024-11-11

By invitation

A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease

NCT06375993Lupus Nephritis, Autoimmune Diseases, Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE)

DrugsADI-001·Fludarabine·Cyclophosphamide

Adicet Therapeutics

Phase 1

180

California, New York

2024-11-10

Recruiting

Natural History Study of Participants With Sanfilippo Syndrome Type IIIC

NCT05825131Sanfilippo Syndrome Type C

Phoenix Nest

Observational

Texas

2024-11-10

Recruiting

Anti-GD2 ADC M3554 in Advanced Solid Tumors

NCT06641908Advanced Solid Tumor

EMD Serono Research & Development Institute, Inc.

Phase 1

Massachusetts, New York, Texas

2024-11-08

Active, closed

Prospective Evaluation of the Tool-in-lesion Technology of the Galaxy System in Routine Clinical Practice

NCT06685133Lung Cancer, Lung; Nodule

Noah Medical

Observational

Tennessee, Virginia

2024-11-08

Active, closed

A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

NCT06614192Metastatic Colorectal Cancer

DrugTelisotuzumab Adizutecan

AbbVie

Phase 2

California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana

2024-11-08

Active, closed

Abbott Medical - VERITAS Study

NCT06707688Atrial Fibrillation (AF), Stoke

Abbott Medical Devices

Not applicable

458

Arizona, Arkansas, Florida, Georgia, Kansas, Michigan, Minnesota, Nebraska

2024-11-07

Recruiting

A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers

NCT05893888Oral Squamous Cell Carcinoma

DrugCisplatin

Privo Technologies

Phase 2/3

California, Florida, Illinois, Ohio

2024-11-07

Active, closed

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

NCT06676319Asthma

DrugsBudesonide/Formoterol·Lunsekimig

Sanofi

Phase 2

556

Alabama, Arizona, California, District of Columbia, Florida, Georgia, Illinois, Kansas

2024-11-07

Active, closed

A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

NCT06659640Hereditary Hemorrhagic Telangiectasia

DrugALN-6400

Alnylam Pharmaceuticals

Phase 1/2

Alabama, California, Florida, Indiana, Massachusetts, Minnesota, Missouri, North Carolina

2024-11-07

Active, closed

A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

NCT06660173Type 2 Diabetes Mellitus (T2DM)

DrugMaridebart cafraglutide

Amgen

Phase 2

409

Alabama, California, Florida, Georgia, Illinois, Louisiana, Michigan, Montana

2024-11-07

By invitation

Prospective Evaluation of Clinical and Radiographic Outcomes Following Total Talus Replacement (PROCLAIM)

NCT06311331Avascular Necrosis of the Talus, Talar Osteochondral Defect of Ankle, Talar Dysfunction

Restor3D

Observational

North Carolina

2024-11-06

Recruiting

A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients

NCT06663358Fabry Disease

DrugPegunigalsidase-alfa

Chiesi Farmaceutici S.p.A.

Observational

100

Alabama, Georgia, Illinois, Iowa, Michigan, Virginia

2024-11-06

Recruiting

Clinical Protocol CERN Feasibility Study

NCT06933420Bacterial Vaginosis, Fungal Vaginal Infections

Cern Corporation

Not applicable

California

2024-11-06

Active, closed

Efficacy and Safety of VDPHL01 in Males With AGA

NCT06724614Androgenetic Alopecia, AGA, Male Pattern Baldness

DrugVDPHL01

Veradermics, Inc.

Phase 2/3

480

Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho

2024-11-06

Recruiting

A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer

NCT06710288Platinum-resistant Ovarian Cancer

DrugsAnktiva·Gemcitabine

ImmunityBio, Inc.

Phase 2

California

2024-11-06

Recruiting

A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)

NCT05582993Von Willebrand Disease (VWD)

DrugsAdvate·Vonicog Alfa

Takeda

Phase 3

Alabama, Florida, Illinois, Indiana, Iowa, Michigan, Minnesota, Nevada

2024-11-06

Recruiting

Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants

NCT06575192Breast Reconstruction

AbbVie

Phase 3

264

California, Colorado, Florida, Illinois, Maryland, Missouri, Nevada, New Jersey

2024-11-05

By invitation

Non-invasive Rejuvenation of the Periorbital Area and Lower Eyelid

NCT07028203Periorbital Wrinkles, Periorbital Area, Under-eyes Dark Circles, Crows Feet

BTL Industries Ltd.

Not applicable

California, Ohio

2024-11-05

Recruiting

FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

NCT06564389Healthy Participants, Atopic Dermatitis

Pfizer

Phase 1

119

California, Florida, Michigan, Pennsylvania

2024-11-05

Recruiting

FastWire REvascularisation of Extremities, (For LOWer Limbs) - FREEFLOW

NCT06492733Chronic Total Occlusion of Artery of the Extremities

Versono Medical Ltd

Not applicable

Delaware, Florida, Iowa, Louisiana, Michigan, Tennessee

2024-11-05

Recruiting

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

NCT06733935Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, Rheumatoid Arthritis

DrugsNKX019·Fludarabine·Cyclophosphamide

Nkarta, Inc.

Phase 1/2

240

California, Florida, Kansas, Michigan, Minnesota, New Jersey, New York, North Carolina

2024-11-04

Recruiting

PULSED AF Post-Approval Study

NCT06578104Atrial Fibrillation

Medtronic Cardiac Ablation Solutions

Observational

580

Florida, Georgia, Illinois, Kentucky, Massachusetts, Michigan, Nebraska, New York

2024-11-04

Recruiting

Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program

NCT06636383Glycogen Storage Disease Type Ia

Ultragenyx Pharmaceutical Inc

Observational

140

California, Colorado, Connecticut, Michigan, North Carolina, Ohio, Pennsylvania, Texas

2024-11-04

Recruiting

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

NCT06298565Myasthenia Gravis

DrugEfgartigimod

argenx

Observational

680

California, Florida, Illinois, Iowa, Kansas, Kentucky, Massachusetts, Michigan

2024-11-04

Active, closed

A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates

NCT06632990Drug Drug Interaction (DDI)

DrugsDextromethorphan·Caffeine·Midazolam

Allyx Therapeutics

Phase 1

Wisconsin

2024-11-04

Active, closed

Impact of GABA Probiotic Lactiplantibacillus Plantarum Lp815 on Sleep Outcomes in Participants with Self-Reported Sleep Disturbance

NCT06789718Insomnia (moderate)

Verb Biotics LLC

Observational

150

California

2024-11-04

Recruiting

A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD

NCT06488313OTC Deficiency, Ornithine Transcarbamylase Deficiency, OTCD

Arcturus Therapeutics, Inc.

Phase 2

Maryland

2024-11-04

Active, closed

A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

NCT06076642Primary Immunodeficiency Diseases (PID)

DrugTAK-881

Takeda

Phase 3

California, Colorado, Florida, Georgia, Illinois, Louisiana, New York, North Carolina

2024-11-04

Active, closed

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

NCT06596694Gastrointestinal Cancer

DrugPatritumab deruxtecan

Merck Sharp & Dohme LLC

Phase 1/2

180

California, Colorado, District of Columbia, Florida, Georgia, Illinois, Nevada, New York

2024-11-03

By invitation

Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures

NCT07092605Longevity, Quality of Life, Mood, Inflammation

DrugsGLP-1·Semaglutide

AgelessRx

Early Phase 1

150

Michigan

2024-11-01

Active, closed

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

NCT06662383Obesity

DrugsRetatrutide·Tirzepatide

Eli Lilly and Company

Phase 3

800

Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois

2024-11-01

Recruiting

Evaluation of Gixam's Performance in a FIT Negative Population

NCT06612281Colorectal Adenoma, Colorectal Cancer (CRC), Colorectal Cancer (CRC) Screening

Jubaan Ltd.

Phase 2

400

Oregon

2024-11-01

Recruiting

A Multi-center, Early Feasibility Study of Using the Mechanical Tissue Resuscitation™ (MTR®) Therapy System for Removal of Excess Fluid in Subjects Who Have Had a Portion of Their Skull Removed to Expose the Dura/Brain and Require Drainage for Fluid Removal.

NCT06201429Clinical Need for Craniotomy or Craniectomy, Clinical Need for Cranioplasty

Renovo Concepts, Inc.

Not applicable

New York, North Carolina, West Virginia

2024-11-01

Recruiting

SynKIR-310 for Relapsed/Refractory B-NHL

NCT06544265B Cell Lymphoma, NHL, Adult, Mantle Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma

DrugSynKIR-310

Verismo Therapeutics

Phase 1

Colorado, Georgia, Kansas, New Jersey, Pennsylvania

2024-11-01

Recruiting

Miro3D Wound Matrix Study for Diabetic Foot Ulcers and Wound Healing

NCT06939686Diabetic Foot Ulcers (DFUs), Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer)

Reprise Biomedical, Inc.

Not applicable

Florida, New York

2024-11-01

Recruiting

A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer

NCT06457503Nasopharyngeal Cancer Recurrent

DrugsJS001·Toripalimab·Gemcitabine·Cisplatin

Coherus Oncology, Inc.

Phase 4

100

Arkansas, California, Georgia, Massachusetts, Michigan, New York, Ohio, Pennsylvania

2024-11-01

Not yet open

Studying Patterns in Patient Engagement Among Treatment Resistant Depression Patients

NCT06101914Treatment Resistant Depression

Power Life Sciences Inc.

Observational

500

California

2024-11

Not yet open

Delving Into Participation Trends in Renal Cell Carcinoma Studies

NCT06093568Renal Cell Carcinoma

Power Life Sciences Inc.

Observational

500

California

2024-11

Not yet open

A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study

NCT06079723Medullary Thyroid Cancer

Power Life Sciences Inc.

Observational

500

California

2024-11

Not yet open

Investigating Participation Patterns Among Stage IV Melanoma Patients

NCT06093594Stage IV Melanoma

Power Life Sciences Inc.

Observational

500

California

2024-11

Not yet open

Revealing Engagement Dynamics Among Diabetic Kidney Disease Patients

NCT06101901Diabetic Kidney Disease

Power Life Sciences Inc.

Observational

500

California

2024-11

Recruiting

Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial

NCT06496256Prostate Cancer

Palette Life Sciences, Inc.

Not applicable

Arizona, California, Florida, Georgia, Massachusetts, New Jersey, Ohio, Pennsylvania

2024-10-31

Recruiting

A Study of DM005 in Patients With Advanced Solid Tumors

NCT06515990Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of Head and Neck, Solid Carcinoma

Doma Biopharmaceutical（Suzhou）Co., Ltd.

Phase 1/2

208

Michigan, Texas, Virginia

2024-10-31

Active, closed

Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism

NCT06531941Hypoparathyroidism

MBX Biosciences

Phase 2

Florida, Georgia, Mississippi, Missouri, Nevada, New York, Ohio, Texas

2024-10-31

Recruiting

Serrantor OCT Study

NCT06434194Critical Limb Ischemia

Cagent Vascular LLC

Not applicable

New York

2024-10-31

Recruiting

A Prospective, Single-arm, Clinical Trial of Electrospun Fiber Matrix (Restrata) in the Treatment of Surgical Defects Secondary to Resection of Malignant Cutaneous Neoplasms

NCT06578650Surgical Wound

Acera Surgical, Inc.

Observational

Nevada

2024-10-31

Active, closed

A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)

NCT06577935Postmenopausal Osteoporosis

Angitia Biopharmaceuticals

Phase 2

379

Alabama, Georgia, New Mexico, Pennsylvania, Washington

2024-10-31

Recruiting

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

NCT06541704Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)

DrugsCemdisiran·Pozelimab

Regeneron Pharmaceuticals

Phase 3

975

Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois

2024-10-30

Active, closed

A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo

NCT06602232Alopecia Areata, Vitiligo

DrugDibotatug

Dren Bio

Phase 1

California, Florida, Georgia, Idaho, Indiana, Massachusetts, Michigan, Pennsylvania

2024-10-30

Active, closed

A Study of ZW191 in Participants With Solid Tumors

NCT06555744Advanced Solid Tumors

Zymeworks BC Inc.

Phase 1

145

Connecticut, Ohio, Oklahoma, Texas, Virginia

2024-10-30

Recruiting

A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma

NCT06630806Plasma Cell Myeloma Refractory

Sanofi

Phase 1

Arizona, Florida, Minnesota, New Jersey, Pennsylvania

2024-10-30

Recruiting

Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia

NCT06451770Hypercholesterolemia, Hypertriglyceridemia, Refractory Hyperlipidemia

Verve Therapeutics, Inc.

Phase 1

132

California, Florida, New York

2024-10-30

Recruiting

Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

NCT06456593Moderately to Severely Active Crohn Disease

DrugObefazimod

Abivax S.A.

Phase 2

212

Alabama, Arizona, California, Colorado, Florida, Illinois, Iowa, Massachusetts

2024-10-30

Active, closed

SpaceIT Hydrogel System for Perirectal Spacing

NCT06451614Prostate Cancer

Boston Scientific Corporation

Not applicable

230

California, Florida, Georgia, Illinois, Kansas, New York, Ohio, Pennsylvania

2024-10-30

Active, closed

A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations

NCT06644768Non-small Cell Lung Cancer, Lung Cancer

DrugsValemetostat·Valemetostat Tosylate·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 1/2

137

California, Florida, Kentucky, Minnesota, New York, Pennsylvania, Virginia

2024-10-30

Recruiting

The THOR IDE Study

NCT05916950Peripheral Artery Disease, Peripheral Artery Stenosis, Peripheral Artery Calcification, PAD

Philips Clinical & Medical Affairs Global

Not applicable

155

California, Colorado, Florida, Iowa, Louisiana, Maine, Massachusetts, Michigan

2024-10-29

Recruiting

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

NCT06663332Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile

DrugGuselkumab

Janssen Research & Development, LLC

Phase 3

196

Georgia, Indiana, Ohio, Texas, Utah

2024-10-29

Active, closed

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

NCT06655896Scleroderma, Diffuse

DrugsRapcabtagene autoleucel·Rituximab

Novartis Pharmaceuticals

Phase 2

California, Florida, Illinois, Iowa, Massachusetts, Michigan, Minnesota, Ohio

2024-10-29

Recruiting

A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)

NCT06657768Alzheimer Disease, Healthy

Eli Lilly and Company

Phase 1

128

California, Florida, Georgia, Michigan, New Jersey, North Carolina

2024-10-29

Active, closed

A Study of Mosliciguat in PH-ILD

NCT06635850Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases

DrugMosliciguat

Pulmovant, Inc.

Phase 2

135

Arizona, California, District of Columbia, Florida, Illinois, Iowa, Kansas, Kentucky

2024-10-29

Recruiting

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

NCT06625775Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors

DrugsBBO-10203·Ribociclib·Folfox·Fulvestrant

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Phase 1

392

California, Florida, Indiana, Massachusetts, Missouri, New York, Tennessee, Texas

2024-10-29

Recruiting

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

NCT06481592Endometrial Cancer

DrugLifileucel

Iovance Biotherapeutics, Inc.

Phase 2

Arizona, California, Florida, Georgia, Kentucky, Michigan, New York, Oklahoma

2024-10-29

Recruiting

Cognition and Imaging With Tigertriever

NCT05531461Stroke

Rapid Medical

Observational

424

California, Michigan, New York, Pennsylvania

2024-10-28

Active, closed

Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

NCT06310031Cardiovascular Diseases, Heart Diseases, Heart Failure

BrioHealth Solutions, Inc.

Not applicable

780

Alabama, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kansas

2024-10-28

Recruiting

Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients

NCT06049680Malnutrition, Child, Malnutrition, Essential Fatty Acid Deficiency (EFAD), Parenteral Nutrition Associated Cholestasis

DrugSMOFlipid

Fresenius Kabi

Phase 4

100

Georgia, Illinois, Indiana, North Carolina, Ohio, Pennsylvania

2024-10-28

Active, closed

Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults

NCT06652100Acute Kidney Injury

BioPorto Diagnostics

Observational

800

Alabama, California, Connecticut, Illinois, Maryland, Massachusetts, Michigan, New Mexico

2024-10-28

Active, closed

A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

NCT06508021Fibrodysplasia Ossificans Progressiva

DrugAndecaliximab

Ashibio Inc

Phase 2/3

California, Minnesota, Pennsylvania

2024-10-25

Active, closed

A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

NCT06413706Glioma

DrugsAbemaciclib·Temozolomide

Eli Lilly and Company

Phase 2

California, Indiana, Maryland, Michigan, Minnesota, Rhode Island, Texas

2024-10-25

Recruiting

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

NCT06638307Advanced Breast Cancer

DrugElacestrant

Stemline Therapeutics, Inc.

Phase 1

240

Arkansas, California, Connecticut, Florida, Georgia, Illinois, Iowa, Kansas

2024-10-25

Recruiting

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

NCT06439082Sickle Cell Disease

DrugCrizanlizumab

Novartis Pharmaceuticals

Phase 3

354

Alabama, California, District of Columbia, Florida, Georgia, Illinois, Kentucky, Maryland

2024-10-24

Active, closed

A Study of DM001 in Patients With Advanced Solid Tumors

NCT06475937Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Solid Carcinoma

Xadcera Biopharmaceutical (Suzhou) Co., Ltd.

Phase 1

128

Tennessee, Texas

2024-10-24

Recruiting

Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring

NCT06668935Diabetes Mellitus

Abbott Diabetes Care

Observational

800

Arizona, Florida, North Carolina, Texas

2024-10-24

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors

NCT06656390Advanced Cancer, Advanced Solid Tumors

Shanghai Allink Biotherapeutics Co., Ltd.

Phase 1/2

202

Colorado, Florida, Louisiana, Tennessee

2024-10-24

Active, closed

Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

NCT06602193Parkinson Disease

Denali Therapeutics Inc.

Phase 2

California, Florida, Massachusetts, New York, Washington

2024-10-24

Recruiting

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

NCT06649110Healthy Volunteers, Pulmonary Arterial Hypertension

Novartis Pharmaceuticals

Phase 1/2

232

Arizona, California, Colorado, Florida, Georgia, Kansas, Kentucky, Massachusetts

2024-10-24

Active, closed

A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

NCT06653153Alzheimer's Disease

DrugRemternetug

Eli Lilly and Company

Phase 3

1,400

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho

2024-10-24

Recruiting

Shoulder Innovations Clinical Data Registry

NCT06754150Shoulder Arthroplasty

Shoulder Innovations

Observational

2,500

Alabama, California, Colorado, Florida, Georgia, Maryland, Massachusetts, Michigan

2024-10-23

Active, closed

Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.

NCT06321601Vasculitis

DrugAvacopan

Amgen

Phase 3

Georgia, Indiana, Minnesota, New York, North Carolina, Ohio, Pennsylvania, Texas

2024-10-22

Recruiting

FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

NCT06669117Solid Tumor, MET Alteration

Pierre Fabre Medicament

Phase 1/2

140

District of Columbia, Ohio, Tennessee

2024-10-22

Recruiting

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

NCT06629779Metastatic Castration-Resistant Prostate Cancer

DrugsMevrometostat·Xtandi·Enzalutamide

Pfizer

Phase 3

900

Arizona, Arkansas, California, Illinois, New Mexico, New York, South Carolina, Texas

2024-10-22

Active, closed

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56

NCT06668064Wet Age Related Macular Degeneration, wAMD

DrugsEYP-1901·Aflibercept

EyePoint Pharmaceuticals, Inc.

Phase 3

400

Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii

2024-10-22

Recruiting

A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia

NCT06651567Agitation Associated With Alzheimer's Dementia

DrugITI-1284

Intra-Cellular Therapies, Inc.

Phase 2

320

California, Florida, Massachusetts, Nevada, New Jersey, North Carolina, Texas

2024-10-22

Recruiting

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

NCT06511141Overactive Bladder, Urinary Urgency Incontinence, Benign Prostatic Hyperplasia, Prostate Cancer

Axonics, Inc.

Not applicable

150

Alabama, Arizona, California, Florida, Louisiana, Maryland, Michigan, Minnesota

2024-10-22

Recruiting

Pilot Study of the Entarik System With Advanced Functionality in Health Adults

NCT06660758Healthy Adults

Gravitas Medical, Inc.

Not applicable

California

2024-10-22

Active, closed

Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis

NCT06450886Inclusion Body Myositis (IBM)

Abcuro, Inc.

Phase 2/3

270

Arizona, California, Connecticut, Massachusetts, New York, North Carolina, Ohio, Pennsylvania

2024-10-21

Active, closed

Comparison of Noninvasive vs. Invasive Hemodynamic Measurements

NCT06689215Heart Failure, Congestive

Nihon Kohden

Observational

California

2024-10-21

Active, closed

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

NCT06551324Metastatic Castrate Resistant Prostate Cancer (mCRPC)

DrugsMevrometostat·Xtandi·Taxotere·Enzalutamide

Pfizer

Phase 3

609

Alabama, Arizona, California, Colorado, Florida, Illinois, Kentucky, Maine

2024-10-21

Recruiting

ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)

NCT06430385Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome

Ionis Pharmaceuticals, Inc.

Phase 1/2

California, Colorado, Maryland, Massachusetts, Minnesota, Pennsylvania, Tennessee, Texas

2024-10-21

Recruiting

Supportive Care Intervention for Outpatient Stem Cell Transplant Patients

NCT06564233Hematopoietic Stem Cell Transplantation, Cancer

Victor Wang

Not applicable

Massachusetts

2024-10-21

Active, closed

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

NCT06643728Obesity, Overweight

DrugsBimagrumab·Tirzepatide

Eli Lilly and Company

Phase 2

252

Alabama, California, Florida, Hawaii, Illinois, Mississippi, Pennsylvania, Washington

2024-10-21

Recruiting

A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature

NCT06382155Idiopathic Short Stature

DrugsHuman Growth Hormone·Vosoritide

BioMarin Pharmaceutical

Phase 2

100

California, District of Columbia, Florida, Georgia, Idaho, Iowa, Kentucky, Louisiana

2024-10-21

Active, closed

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor

Drugs5Fluorouracil·Leucovorin·Irinotecan·Cetuximab

Eli Lilly and Company

Phase 1

750

Alabama, Arizona, California, Connecticut, Illinois, Indiana, Massachusetts, Michigan

2024-10-21

Recruiting

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

NCT06623422Carcinoma, Non-Small-Cell Lung

DrugsIntismeran autogene·Paraplatin·Taxol·Pemetrexed

Merck Sharp & Dohme LLC

Phase 3

680

Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois, Indiana

2024-10-21

Active, closed

Esprit BTK Post-Approval Study

NCT06656364Chronic Limb-Threatening Ischemia

Abbott Medical Devices

Not applicable

200

Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana

2024-10-21

Recruiting

Controlled Desaturation Study for Perin Health Patch Validation

NCT06680700Oxygen Saturation Measurement

Perin Health Devices

Observational

California

2024-10-21

Recruiting

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

NCT06619860Diabetic Peripheral Neuropathic Pain

DrugPregabalin

Vertex Pharmaceuticals Incorporated

Phase 2

300

Alabama, California, Colorado, Florida, Georgia, Idaho, Illinois, Michigan

2024-10-18

Recruiting

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors

NCT06598800Advanced Solid Tumor

BeOne Medicines

Phase 1

153

New Jersey, Texas, Virginia, Wisconsin

2024-10-18

Recruiting

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

NCT06544499Primary Immune Thrombocytopenia (ITP)

DrugEfgartigimod

argenx

Phase 3

Arizona, California, Colorado, Connecticut, District of Columbia, Illinois, Iowa, Louisiana

2024-10-18

Recruiting

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

NCT06662786Colorectal Neoplasms

DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Irinotecan

Janssen Research & Development, LLC

Phase 3

1,000

Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia

2024-10-18

Active, closed

A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

NCT06643481Amyotrophic Lateral Sclerosis (ALS)

DrugVHB937

Novartis Pharmaceuticals

Phase 2

251

California, Florida, Georgia, Kansas, Massachusetts, Nebraska, New York, North Carolina

2024-10-17

Recruiting

The RAPID - PE Study: RESCUE Advanced Protocol for the Treatment of Pulmonary Embolism

NCT06433011Pulmonary Embolism

Thrombolex, Inc.

Not applicable

500

Arizona, Florida, Georgia, Illinois, Indiana, Massachusetts, Mississippi, New Hampshire

2024-10-17

Active, closed

IC14 for Treatment of Acute Decompensated Heart Failure

NCT06556810Acute Decompensated Heart Failure

DrugAtibuclimab

Implicit Bioscience

Phase 1/2

Virginia

2024-10-17

Active, closed

J-Valve Transfemoral Pivotal Study

NCT06455787Aortic Valve Regurgitation, Aortic Valve Disease Mixed

JC Medical, Inc., an affiliate of Edwards Lifesciences LLC

Not applicable

194

Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Kansas

2024-10-17

By invitation

A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )

NCT06559176Chronic Granulomatous Disease, Granulomatous Disease, Chronic

Prime Medicine, Inc.

Phase 1/2

California, Maryland, Tennessee

2024-10-17

Recruiting

Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder

NCT06538558Opioid Use Disorder

Proniras Corporation

Phase 1

Indiana

2024-10-16

Recruiting

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

NCT06055959Generalized Myasthenia Gravis

DrugZilucoplan

UCB Biopharma SRL

Phase 2/3

Illinois, Texas

2024-10-16

Active, closed

A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma

NCT06637371Asthma

DrugAMG 691

Amgen

Phase 1

California, Florida, Georgia, Maryland, Massachusetts, Minnesota, North Carolina, Oklahoma

2024-10-16

Recruiting

Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT06549790Relapsed/Refractory Acute Myeloid Leukemia

Nerviano Medical Sciences

Phase 1

124

California, Colorado, Delaware, Georgia, Minnesota, Ohio, Texas

2024-10-16

Active, closed

A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis

NCT06598462Eosinophilic Esophagitis (EoE)

DrugSolrikitug

Uniquity One (UNI)

Phase 2

184

Alabama, Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois

2024-10-16

Active, closed

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

NCT06625320Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

DrugsLiposomal Irinotecan·Leucovorin·Irinotecan·Cetuximab

Revolution Medicines, Inc.

Phase 3

500

Arizona, California, Colorado, Florida, Hawaii, Illinois, Maryland, Massachusetts

2024-10-16

Active, closed

A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine

NCT06581575Herpes Zoster (HZ), Infectious Diseases, Shingles

DrugShingrix

Immorna Biotherapeutics, Inc.

Phase 2

467

Arizona, California, Illinois, Nebraska, New Jersey, South Carolina, Texas

2024-10-16

Recruiting

A Prospective Study to Develop and Clinically Validate an in Vitro Diagnostic Medical Device That Uses Blood to Classify Patients at High Risk for Breast Cancer

NCT06672302Breast Neoplasm

EXoPERT

Observational

330

Hawaii

2024-10-16

Recruiting

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

NCT06663319Colorectal Neoplasms, Gastrointestinal Neoplasms

DrugsFolfox·Bevacizumab

Janssen Research & Development, LLC

Phase 1

260

Arizona, Colorado, Florida, Indiana, Michigan, Washington

2024-10-15

Active, closed

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

NCT06641076Arthritis, Psoriatic

DrugSonelokimab

MoonLake Immunotherapeutics AG

Phase 3

960

Arizona, California, Florida, Illinois, Louisiana, Maryland, Michigan, North Carolina

2024-10-15

By invitation

The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)

NCT06276764IPMN, Pancreatic, Pancreas Cancer, Pancreatic Cyst

Adenocyte, LLC

Observational

500

New York

2024-10-15

Active, closed

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

NCT06564844Non-small Cell Lung Cancer

DrugsRilvegostomig·Dato-DXd·Vinorelbine·Etoposide

AstraZeneca

Phase 3

Arizona, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky

2024-10-15

Active, closed

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

NCT06641089Arthritis, Psoriatic

DrugsSonelokimab·Risankizumab

MoonLake Immunotherapeutics AG

Phase 3

600

Arizona, Arkansas, California, Florida, Georgia, Illinois, Louisiana, Maryland

2024-10-15

Recruiting

Study of ATX-01 in Participants With DM1

NCT06300307Myotonic Dystrophy 1

ARTHEx Biotech S.L.

Phase 1/2

California, Florida, Iowa, Kansas, Virginia

2024-10-15

Recruiting

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

NCT06562192Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer

Novartis Pharmaceuticals

Phase 1

162

Alabama, California, Florida, Massachusetts, Michigan, Minnesota, Texas, Washington

2024-10-15

Recruiting

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

NCT06632444Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis

Boehringer Ingelheim

Phase 3

1,800

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana

2024-10-14

Recruiting

FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer

NCT06636682Prostate Cancer (Adenocarcinoma), Prostate CA, Prostate Cancers, Prostate Cancer (Post Prostatectomy)

Cellvax Therapeutics Inc

Phase 2

100

Illinois, Ohio, South Carolina

2024-10-14

Recruiting

Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)

NCT06486454Liver Neoplasms, Primary Liver Cancer, Secondary Liver Cancer, Tumor Liver

HistoSonics, Inc.

Observational

5,000

Alabama, California, Florida, Georgia, Illinois, Louisiana, Maryland, Massachusetts

2024-10-14

Active, closed

A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)

NCT06504394Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Primary Mediastinal Large B-cell Lymphoma Recurrent, Primary Mediastinal Large B-cell Lymphoma Refractory

Drugs) Berahyaluronidase alfa·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

Iowa, Nevada, New York

2024-10-14

Recruiting

Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

NCT06679270Familial Partial Lipodystrophy

DrugMetreleptin

Chiesi Farmaceutici S.p.A.

Phase 3

Alabama, Florida, Massachusetts, Michigan, Pennsylvania, Texas, Wisconsin

2024-10-14

Active, closed

Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)

NCT06553768Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)

DrugMaralixibat

Mirum Pharmaceuticals, Inc.

Phase 3

California, Illinois, New York, Ohio, Texas, Utah

2024-10-14

Active, closed

Prospective Case Collection Study of Contrast-Enhanced Mammography Imaging Acquired on a New Investigational Device

NCT06636539Breast Screening

Hologic, Inc.

Not applicable

Texas, Virginia

2024-10-14

Active, closed

Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy

NCT06453213Focal Onset Seizure

DrugCenobamate

SK Life Science, Inc.

Phase 4

Arizona, Arkansas, California, Connecticut, Florida, Idaho, Kentucky, Louisiana

2024-10-14

Active, closed

A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment

NCT06447168Primary Biliary Cholangitis

Ipsen

Observational

424

California, Colorado, Connecticut, Florida, Massachusetts, New Jersey, New York, North Carolina

2024-10-14

Active, closed

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

NCT06388564Chronic Graft-versus-host-disease

DrugsAxatilimab·Ruxolitinib·Prednisolone·Methylprednisolone

Incyte Corporation

Phase 2

130

Arizona, California, Colorado, Connecticut, Florida, Illinois, Maryland, Missouri

2024-10-11

Recruiting

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

NCT06581432Solid Tumours

DrugZongertinib

Boehringer Ingelheim

Phase 2

588

Alaska, Arizona, California, Connecticut, Florida, Illinois, Indiana, Maryland

2024-10-11

Active, closed

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

NCT06516965Prurigo Nodularis

DrugPovorcitinib

Incyte Corporation

Phase 3

346

Arizona, California, Florida, Kentucky, Maryland, Massachusetts, Michigan, New Hampshire

2024-10-10

Recruiting

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

NCT06619990Ulcerative Colitis (UC)

Xencor, Inc.

Phase 1/2

270

Arizona, California, Florida, Kentucky, Mississippi, New York, North Carolina, Ohio

2024-10-10

Active, closed

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

NCT06598943Ulcerative Colitis, Ulcerative Colitis Chronic

DrugMirikizumab

Eli Lilly and Company

Phase 2

143

Arizona, Arkansas, California, Colorado, Connecticut, Florida, Illinois, Louisiana

2024-10-10

Active, closed

A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)

NCT06646289X-Linked Retinitis Pigmentosa

MeiraGTx Ocular UK Ltd

Phase 2

Massachusetts, Michigan

2024-10-10

Active, closed

A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

NCT06625060Episodic Migraine, Chronic Migraine

DrugCorabotase

Ipsen

Phase 2

670

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Louisiana

2024-10-10

Active, closed

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)

NCT06516952Prurigo Nodularis

DrugPovorcitinib

Incyte Corporation

Phase 3

349

Alabama, Arizona, Arkansas, California, Florida, Illinois, Indiana, Michigan

2024-10-10

Active, closed

A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

NCT06544655Advanced Solid Tumors

DrugsCalcium folinate·Fluorouracil·Opdivo·Nivolumab

Bristol-Myers Squibb

Phase 1

213

Arizona, California, Michigan, South Dakota, Texas

2024-10-10

Active, closed

Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa

NCT06361836Hidradenitis Suppurativa

DrugSBT777101

Sonoma Biotherapeutics, Inc.

Phase 1

Massachusetts, Minnesota, Missouri, New York, North Carolina, Texas

2024-10-09

Active, closed

Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)

NCT05417789TGCT

DrugEmactuzumab

SynOx Therapeutics Limited

Phase 3

128

California, Ohio, Texas, Washington

2024-10-09

Recruiting

A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia

NCT06525636X-linked Hypophosphatemia

Kyowa Kirin Co., Ltd.

Phase 1/2

California, Connecticut, Indiana, Minnesota, Tennessee

2024-10-09

Active, closed

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

NCT06470048Diffuse Cutaneous Systemic Sclerosis

DrugIanalumab

Novartis Pharmaceuticals

Phase 2

201

Arizona, California, Florida, Illinois, Michigan, New York, Tennessee, Texas

2024-10-09

Active, closed

Regenn® Therapy System Safety Study

NCT06259409Surgical Wound

Progenerative Medical, Inc

Phase 1

Kansas

2024-10-09

Active, closed

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1

NCT06630286HIV-1-infection

DrugsISL/LEN·B/F/TAF

Gilead Sciences

Phase 3

609

Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia

2024-10-09

Recruiting

DermaSensor Postmarket Surveillance Study

NCT06666790Melanoma, Skin

DermaSensor, Inc.

Not applicable

396

Florida, North Carolina

2024-10-08

Active, closed

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1

NCT06630299HIV-1-Infection

DrugsAntiretroviral Combinations·ISL/LEN

Gilead Sciences

Phase 3

600

Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia

2024-10-08

Active, closed

A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

NCT06672055SARS-CoV2, COVID-19

DrugComirnaty

Vaxart

Phase 2

5,485

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida

2024-10-08

Recruiting

Study of ACR-2316 in Specific Advanced Solid Tumors

NCT06667141Specific Advanced Solid Tumors

Acrivon Therapeutics

Phase 1/2

100

Arizona, California, Colorado, Florida, Massachusetts, Michigan, New York, North Carolina

2024-10-08

Recruiting

A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease

NCT06566170Alzheimer Disease

DrugDonanemab

Eli Lilly and Company

Observational

6,250

Alabama

2024-10-07

Recruiting

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

NCT06561386Non-small Cell Lung Cancer

DrugsRelatlimab·Pemetrexed·Nivolumab·Cisplatin

Bristol-Myers Squibb

Phase 3

1,000

Alabama, Arizona, California, Colorado, Florida, Idaho, Illinois, Kansas

2024-10-07

Active, closed

A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

NCT06602479Migraine

AbbVie

Phase 2

309

Alabama, Arizona, California, Florida, New Mexico, New York, Oklahoma, Pennsylvania

2024-10-07

Recruiting

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

NCT06598306Extensive Stage Small Cell Lung Cancer

DrugTarlatamab

Amgen

Phase 1

220

California, Illinois, Michigan, South Dakota, Texas, Washington

2024-10-07

Active, closed

A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) - Long Lesion Cohort

NCT06492174In-Stent Restenosis

Boston Scientific Corporation

Phase 3

Arizona, California, Georgia, Michigan, New York, Ohio, Pennsylvania, Rhode Island

2024-10-07

Recruiting

Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN

NCT06527872Lupus Nephritis

GlaxoSmithKline

Observational

300

Maryland, North Carolina, Ohio, Tennessee

2024-10-04

Recruiting

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis

DrugEfruxifermin

Akero Therapeutics, Inc

Phase 3

2,150

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida

2024-10-04

Recruiting

CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)

NCT06420089T Cell Non-Hodgkin Lymphoma

Vittoria Biotherapeutics

Phase 1

New York, Pennsylvania

2024-10-04

Active, closed

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06417814Metastatic Non-small Cell Lung Cancer

DrugsTagrisso·Dato-DXd·Osimertinib·Pemetrexed

AstraZeneca

Phase 3

768

Arkansas, California, Florida, Missouri, New York, Ohio, Pennsylvania, Tennessee

2024-10-04

Recruiting

A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants

NCT06625671Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus

DrugPrednisone

DualityBio Inc.

Phase 1/2

148

California, Florida, New York, Texas

2024-10-04

Active, closed

A Prospective, Observational Study in Adults With Retinitis Pigmentosa (RP)

NCT06517940Retinitis Pigmentosa

Sumitomo Pharma America, Inc.

Observational

Massachusetts

2024-10-03

Recruiting

A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

NCT06343805Primary Myelofibrosis

Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company

Phase 1

256

California, Florida, Kansas, Massachusetts, Michigan, Missouri, New York, North Carolina

2024-10-03

Recruiting

Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)

NCT05947955Acute Respiratory Distress Syndrome, Infections

BioAegis Therapeutics Inc.

Phase 2

600

California, Georgia, Illinois, Kentucky, Minnesota, Missouri, New York, Pennsylvania

2024-10-03

Recruiting

A Study of BG-C477 in Participants With Advanced Solid Tumors

NCT06596473Advanced Solid Tumors

DrugTislelizumab

BeOne Medicines

Phase 1

310

Arizona, California, Colorado, Connecticut, Illinois, Kansas, Mississippi, New Jersey

2024-10-03

Recruiting

THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension

NCT06559891Hypertension

SoniVie Inc.

Not applicable

261

Alabama, Arizona, Arkansas, California, Connecticut, Florida, Illinois, Louisiana

2024-10-03

Recruiting

Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis

NCT06686472Allergic Conjunctivitis

DrugTL-925

Telios Pharma, Inc.

Phase 2

Tennessee

2024-10-03

Recruiting

A Clinical Trial to Assess the Efficacy and Tolerance of a Berberine-based Nutraceutical Formula to Aid Blood Sugar Regulation and Metabolism

NCT06700915Metabolism Disorder, Nutraceutical

Ultimate International, Inc.

Not applicable

California

2024-10-03

Active, closed

Assessment of Heart Rate Measurement Accuracy for the PreemptiveAI SDK in Adults

NCT06696339Heart Rate in the General Public

PreemptiveAI, Inc

Observational

100

Washington

2024-10-03

Recruiting

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

NCT06561048Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype

DrugsBelinostat·Pralatrexate·Soquelitinib

Corvus Pharmaceuticals, Inc.

Phase 3

150

California, Connecticut, Florida, Georgia, Illinois, Iowa, Maryland, Massachusetts

2024-10-02

Active, closed

A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

NCT06568237Multiple System Atrophy

DrugEmrusolmin

Teva Branded Pharmaceutical Products R&D LLC

Phase 2

349

California, District of Columbia, Florida, Illinois, Kansas, Massachusetts, Michigan, Minnesota

2024-10-02

Recruiting

A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946

NCT06616766NSCLC (Non-small Cell Lung Cancer), Solid Tumor

Yuhan Corporation

Phase 1/2

201

Virginia

2024-10-02

Recruiting

ALTO-100 in Bipolar Disorder With Depression (BD-D)

NCT06656416Bipolar Disorder I or II With a Major Depressive Episode

Alto Neuroscience

Phase 2

200

Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois

2024-10-02

Recruiting

Modulation of SERCA2a of Intra-Myocytic Calcium Trafficking in Cardiomyopathy Secondary to Duchenne Muscular Dystrophy

NCT06224660DMD-Associated Dilated Cardiomyopathy

Sardocor Corp.

Phase 1

Kansas, Ohio

2024-10-02

Active, closed

Heidelberg Engineering ANTERION Software Comparison Study

NCT06657716Eyes With Normal Anterior Segment, Eyes With Abnormal Anterior Segment

Heidelberg Engineering GmbH

Observational

Minnesota

2024-10-02

Recruiting

Safety and Effectiveness of Slow Wave Device for the Treatment of Obstructive Sleep Apnea

NCT06519149Obstructive Sleep Apnea

Slow Wave, Inc.

Observational

Texas

2024-10-01

Active, closed

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

NCT06506955Advanced/Metastatic Cancer

DrugFutibatinib

Taiho Oncology, Inc.

Phase 2/3

California

2024-10-01

Recruiting

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

NCT06510374Intermediate Risk Non-Muscle Invasive Bladder Cancer

DrugNadofaragene Firadenovec

Ferring Pharmaceuticals

Phase 3

454

Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia

2024-10-01

Active, closed

SIMPLAAFY Clinical Trial

NCT06521463Atrial Fibrillation, Stroke, Bleeding

Boston Scientific Corporation

Not applicable

1,857

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida

2024-10-01

Recruiting

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

NCT06628908Diabetic Peripheral Neuropathic Pain

DrugsSuzetrigine·Pregabalin

Vertex Pharmaceuticals Incorporated

Phase 3

1,100

Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho

2024-10-01

Recruiting

A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis

NCT06671054Rheumatoid Arthritis (RA)

DrugAP1189

SynAct Pharma Aps

Phase 2

240

Florida, Pennsylvania

2024-10-01

Recruiting

Urine Metabolites in the Diagnosis of Disease

NCT06710067Colorectal Cancer, Small Intestinal Bacterial Overgrowth Syndrome (SIBO), Crohn Disease, Celiac Disease

Luventix, Inc.

Observational

1,250

California

2024-10-01

Recruiting

Infant Formula in Infants and Children With Cow's Milk Allergy

NCT06456541Cow's Milk Allergy

Abbott Nutrition

Not applicable

Arizona, Colorado, Illinois, Michigan, North Carolina, Ohio, Texas

2024-10-01

Recruiting

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

NCT06634394Acute Myeloid Leukemia (AML)

DrugsVenclexta·Azacitidine·Venetoclax

Aptevo Therapeutics

Phase 1

Colorado, Florida, Kansas, Ohio, Texas

2024-10-01

Recruiting

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

NCT06545955Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

DrugsNadofaragene Firadenovec·Docetaxel·Gemcitabine·Pembrolizumab

Ferring Pharmaceuticals

Phase 3

250

Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia

2024-10-01

Recruiting

Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Knee Osteoarthritis

NCT06608134Osteoarthritis, Knee

R3 Medical Research

Early Phase 1

120

Arizona, California, New York, Texas

2024-10-01

By invitation

Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients

NCT06657859Pmm2-CDG, Phosphomannomutase 2 Deficiency

Glycomine, Inc.

Phase 2

Minnesota, New York, Pennsylvania, Washington

2024-09-30

Recruiting

A Study on TLC590 for Managing Postsurgical Pain

NCT06574269Postsurgical Pain Management

DrugsTLC590·Ropivacaine

TLC Biopharmaceuticals, Inc.

Phase 2

120

Texas

2024-09-30

Active, closed

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

NCT06473779Severe Asthma

AstraZeneca

Phase 3

310

California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Oklahoma, Texas

2024-09-30

By invitation

Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma

NCT06609239Asthma

DrugLunsekimig

Sanofi

Phase 2

900

Arizona, Colorado, Florida, Georgia, Massachusetts, Michigan, Missouri, North Carolina

2024-09-30

Active, closed

Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects

NCT06471543Hypertriglyceridemia, Familial Chylomicronemia Syndrome

Ikaria Bioscience Pty Ltd

Phase 1/2

108

Florida, Kentucky, Minnesota, Texas, Utah

2024-09-30

Recruiting

A Multi-Site Clinical Evaluation of the LIAISON NES FLU A/B, RSV & COVID-19 Assay in Symptomatic Patients

NCT06672692Influenza a, Influenza B, RSV, COVID 19

DiaSorin Molecular LLC

Not applicable

1,000

Nevada, Pennsylvania, Texas

2024-09-30

Recruiting

Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment

NCT06740799Hepatic Impairment

DrugQuizartinib

Daiichi Sankyo

Phase 1

Florida

2024-09-30

Active, closed

A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease

NCT06602258Alzheimer's Disease

DrugsE2814·Lecanemab

Eisai Inc.

Phase 2

105

Arizona, Connecticut, Florida, Georgia, Mississippi, Missouri, Pennsylvania, Tennessee

2024-09-30

Active, closed

A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body

NCT06421636Non-Transfusion Dependent Beta-Thalassemia (NTDT)

Regeneron Pharmaceuticals

Phase 2

New York

2024-09-30

Recruiting

Phase III Presbyopia Correction Using the VIS Opti-K™ System

NCT06487897Presbyopia

VIS, Inc.

Phase 3

Florida, Massachusetts, New Jersey, New York

2024-09-30

Recruiting

A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

NCT06551142Neoplasms

DrugsRis-Rez·Tarlatamab·Dostarlimab·Cetuximab

GlaxoSmithKline

Phase 1

845

California, Colorado, Connecticut, Indiana, Massachusetts, Michigan, New Jersey, South Carolina

2024-09-30

Active, closed

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

NCT06492616Breast Cancer

DrugsElacestrant·Tamoxifen·Exemestane·Anastrozole

Stemline Therapeutics, Inc.

Phase 3

4,556

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida

2024-09-27

Recruiting

Registry for Stage 2 Type 1 Diabetes

NCT06481904Type 1 Diabetes

DrugTzield

Sanofi

Observational

200

California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky

2024-09-27

Recruiting

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease

NCT06613698Liver Diseases, Alcoholic

DrugGSK4532990

GlaxoSmithKline

Phase 2

393

Arizona, California, Florida, Georgia, Indiana, Kansas, Louisiana, Michigan

2024-09-27

Recruiting

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

NCT06463665Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma

DrugsOlvi-Vec·Olvimulogene nanivacirepvec·Docetaxel·Cisplatin

Genelux Corporation

Phase 2

142

Arizona, Florida, Michigan, New Jersey, Ohio, Texas

2024-09-26

Recruiting

Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

NCT06584357Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss

GAP Innovations, PBC

Observational

1,200

Florida, Illinois, Michigan, Nevada, New York, Ohio, Pennsylvania, Rhode Island

2024-09-26

Recruiting

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

NCT06585787Alzheimer Disease

DrugKarXT

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

406

Arizona, California, Connecticut, Florida, Georgia, Massachusetts, Michigan, Mississippi

2024-09-26

Active, closed

TraNsvenous TrIcuspid Valve ReplacemenT With LuX-Valve Plus System (TRINITY-US)

NCT06568003Tricuspid Regurgitation (TR)

Jenscare Innovation Inc.

Not applicable

California, Michigan, New York

2024-09-26

Active, closed

A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725

NCT06539507Netherton Syndrome

BioCryst Pharmaceuticals

Phase 1

California, Connecticut, Illinois, Indiana

2024-09-26

Active, closed

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis

DrugNerandomilast

Boehringer Ingelheim

Phase 3

1,666

Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida

2024-09-26

Active, closed

A Multi-Centre Study in Patients Undergoing Total Hip Arthroplasty With the Smith+Nephew CATALYSTEM™ Primary Hip System

NCT06564636Total Hip Arthroplasty (THA), Osteoarthritis, Degenerative Joint Disease, Inflammatory Arthritis

Smith & Nephew, Inc.

Observational

119

California, Connecticut, Florida, Illinois, New York, North Carolina

2024-09-26

Active, closed

ADVENT Post Approval Study

NCT06431815Paroxysmal Atrial Fibrillation

Boston Scientific Corporation

Observational

228

Alabama, Arizona, California, District of Columbia, Florida, Georgia, Louisiana, Massachusetts

2024-09-25

Recruiting

Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT

NCT06564974Duchenne Muscular Dystrophy

DrugVamorolone

Catalyst Pharmaceuticals, Inc.

Observational

250

Arizona, Arkansas, California, District of Columbia, Florida, Illinois, Indiana, Kansas

2024-09-25

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

NCT06525220Head and Neck Squamous Cell Carcinoma

DrugsPetosemtamab·Pembrolizumab

Genmab

Phase 3

699

Alabama, California, Delaware, District of Columbia, Florida, Georgia, Illinois, Kentucky

2024-09-25

Active, closed

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

NCT06660394Dravet Syndrome

DrugBexicaserin

Longboard Pharmaceuticals

Phase 3

108

Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Maryland

2024-09-25

Recruiting

A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)

NCT06462235Gram-negative Bacterial Infection

Pfizer

Phase 2

California, Colorado, Indiana, Kentucky, Massachusetts, North Carolina, Texas

2024-09-25

Active, closed

A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV

NCT06564194Respiratory Syncytial Virus (RSV), Infectious Disease

Immorna Biotherapeutics, Inc.

Phase 1

Florida, Louisiana, Missouri

2024-09-25

Recruiting

A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems

NCT06512454Alpha1-Antitrypsin Deficiency

Takeda

Observational

500

Florida, South Carolina, Tennessee

2024-09-25

Active, closed

A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy

NCT06481891Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy

DrugSotagliflozin

Lexicon Pharmaceuticals

Phase 3

500

Arizona, California, Florida, Georgia, Illinois, Indiana, Maryland, Massachusetts

2024-09-24

Active, closed

A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis

NCT06592794Acute Gastroenteritis, Norovirus Acute Gastroenteritis

ModernaTX, Inc.

Phase 3

37,864

Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho

2024-09-24

Active, closed

A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)

NCT06436742Congenital Myasthenic Syndrome, CMS

DrugARGX-119

argenx

Phase 1

California, Illinois

2024-09-24

Active, closed

Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough

NCT06504446Refractory or Unexplained Chronic Cough

Nocion Therapeutics

Phase 2

455

Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois

2024-09-24

Active, closed

Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer

NCT06555796Prostate Cancer, High-risk Biochemical Recurrence, High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer, Non-metastatic Castration-sensitive Prostate Cancer

DrugXaluritamig

Amgen

Phase 1

Minnesota, New York, North Carolina, Oregon, Pennsylvania, Texas, Washington

2024-09-23

Recruiting

Dehydrated Human Amnion Membrane and Standard of Care Versus Standard of Care Alone in Nonhealing Diabetic Foot Ulcers

NCT06550596Diabetic Foot, Ulcer Foot, Foot Ulcer, Diabetic Foot Ulcer

Axolotl Biologix

Not applicable

100

California

2024-09-23

Recruiting

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

NCT06413680Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors

DrugsREGN10597·Cemiplimab

Regeneron Pharmaceuticals

Phase 1/2

240

California, Connecticut, Illinois, Michigan, New York, North Carolina, Pennsylvania, Texas

2024-09-23

Recruiting

Investigation of a Device to Deliver Intra-Operative Therapeutic Hypothermia for Hearing Preservation in Cochlear Implantation

NCT06375278Cochlear Implants, Cochlear Implantation, Hearing Loss

Restorear Devices LLC

Not applicable

Florida

2024-09-23

Active, closed

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06497556Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer

DrugsDivarasib·Adagrasib·Sotorasib

Hoffmann-La Roche

Phase 3

338

Arizona, California, Connecticut, Florida, Illinois, Maine, Massachusetts, Michigan

2024-09-23

Recruiting

Non-Euploid Embryo Transfer (NEET) Registry

NCT07036536Infertility, Mosaicism, Aneuploidy

Inception Fertility Research Institute, LLC

Observational

1,000

Texas

2024-09-23

Recruiting

A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDT

NCT05171894Port-wine Birthmarks, Port-Wine Stain, Nevus Flammeus

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Phase 2

California, Florida, Maryland, Pennsylvania

2024-09-21

Recruiting

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

NCT06469944Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer

DrugsPatritumab deruxtecan·Xeloda·Sacituzumab tirumotecan·Leucovorin

Merck Sharp & Dohme LLC

Phase 1/2

160

Arizona, California, Kentucky, Michigan, New York, Pennsylvania, Texas

2024-09-20

Active, closed

To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

NCT06553027Parkinson Disease

Cerevance

Phase 3

330

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Kansas

2024-09-20

Recruiting

Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)

NCT06633016Major Depressive Disorder

DrugABX-002

Autobahn Therapeutics, Inc.

Phase 2

230

Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Massachusetts

2024-09-20

Active, closed

KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis

NCT06384976Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, MS

DrugKYV-101

Kyverna Therapeutics

Phase 2

120

California

2024-09-20

Recruiting

Evaluating the Efficacy of a Single Layer Placental-based Allograft and Standard of Care Versus Standard of Care

NCT06564831Diabetic Foot Ulcer, Diabetic Foot, Foot Ulcer, Ulcer Foot

Applied Biologics, LLC

Not applicable

124

Michigan

2024-09-20

Recruiting

A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors

NCT06598007Solid Tumor, Adult, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma

DrugFolfox

Crossignal Therapeutics, Inc.

Phase 1/2

Texas

2024-09-20

Recruiting

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

NCT06586957Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Metastatic Tumor

DrugsDoxorubicin·Paclitaxel

NiKang Therapeutics, Inc.

Phase 1

238

Arkansas, California, Colorado, Florida, Georgia, Kansas, Massachusetts, New Jersey

2024-09-19

Recruiting

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

NCT06561685Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor

DrugsNab-paclitaxel·Pemetrexed·Paclitaxel·Cisplatin

Eli Lilly and Company

Phase 1

340

California, Colorado, Florida, Illinois, Massachusetts, New York, Ohio, Tennessee

2024-09-19

Active, closed

A Multicenter, Retrospective, Chart Review Study Evaluating the Impact and Utility of the Blood-Based Proteomic Integrated Classifier and Auto-Antibody Tests in the Real-World

NCT06728319Lung Nodules

Biodesix, Inc.

Observational

4,000

Florida, Kentucky, Massachusetts, Pennsylvania

2024-09-19

Recruiting

INNOVEN: Efficacy of Porcine Placental Extracellular Matrix Plus Standard of Care (SOC) Versus SOC Alone

NCT06606210Wound Heal, Venous Leg Ulcer

ConvaTec Inc.

Not applicable

120

Florida

2024-09-19

Recruiting

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

NCT06635148Geographic Atrophy, Macular Degeneration

Janssen Research & Development, LLC

Phase 2/3

274

Arizona, California, Florida, Georgia, Illinois, Indiana, Maine, Maryland

2024-09-19

Active, closed

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

NCT06190951Melanoma

DrugsFianlimab·Cemiplimab

Regeneron Pharmaceuticals

Phase 2

151

California, Colorado, Connecticut, Georgia, Illinois, Massachusetts, Missouri, New Jersey

2024-09-18

Active, closed

NS-050/NCNP-03 in Boys With DMD (Meteor50)

NCT06053814Duchenne Muscular Dystrophy

NS Pharma, Inc.

Phase 1/2

California, Colorado, Illinois, Kansas, Pennsylvania

2024-09-18

Active, closed

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

NCT06558279Myasthenia Gravis, Ocular

argenx

Phase 3

141

Arizona, California, Florida, Illinois, Maryland, Massachusetts, Michigan, New Jersey

2024-09-18

Recruiting

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

NCT06542250B-cell Malignancies

DrugAZD5492

AstraZeneca

Phase 1/2

174

California, Massachusetts, Minnesota, New Jersey, New York, North Carolina, Texas, Washington

2024-09-18

Active, closed

A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06589986Moderately to Severely Active Ulcerative Colitis

DrugAfimkibart

Hoffmann-La Roche

Phase 3

400

Alabama, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana

2024-09-17

Recruiting

An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

NCT06398626Colitis, Ulcerative

DrugEtrasimod

Pfizer

Observational

300

Arizona, California, Colorado, Florida, Illinois, Maryland, New Jersey, New York

2024-09-17

Active, closed

A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

NCT06559163Systemic Lupus Erythematosus

DrugObexelimab

Zenas BioPharma (USA), LLC

Phase 2

190

Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana, Maryland

2024-09-17

Active, closed

Detection and Classification of Cardiac Rhythm and Atrial Fibrillation Using a Finger-worn Ring

NCT06892938Atrial Fibrillation (AF), Arrhythmias Cardiac, Tachycardia, Palpitations

Everbeat

Observational

232

California, Louisiana, Pennsylvania

2024-09-17

Active, closed

A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy

NCT06537999Multifocal Motor Neuropathy

DrugClaseprubart

Dianthus Therapeutics

Phase 2

Arizona, California, Florida, Hawaii, Kansas, Ohio, Texas

2024-09-17

Active, closed

STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss

NCT06571383Obesity

DrugSemaglutide

Novo Nordisk A/S

Phase 4

500

California, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Louisiana

2024-09-17

Active, closed

Safety and Effectiveness of Cochlear Implantation in an Expanded Adult Population

NCT06293482Hearing Loss, Sensorineural, Hearing Loss, Bilateral

Cochlear

Not applicable

Arizona, California, Florida, Indiana, Missouri, New York, Ohio, Pennsylvania

2024-09-17

Recruiting

Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

NCT06567015Non-small Cell Lung Cancer (NSCLC)

Pierre Fabre Medicament

Phase 1/2

171

Tennessee, Texas

2024-09-17

Active, closed

Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)

NCT06497504Hepatitis B

DrugBepirovirsen

GlaxoSmithKline

Phase 2

153

California, Florida, Maryland, Minnesota, New Jersey

2024-09-17

Active, closed

Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

NCT06333951Thoracic Tumors, Non-small Cell Lung Cancer

DrugsAnvumetostat·Sotorasib·Pemetrexed·Paclitaxel

Amgen

Phase 1

California, Colorado, Connecticut, Minnesota, Missouri, Nevada, New York, Oklahoma

2024-09-17

Recruiting

Regulatory Clearance of the Glide Control Strategy for Upper Limb Prostheses

NCT06539936Amputation, Upper Limb

Infinite Biomedical Technologies

Not applicable

California

2024-09-16

Recruiting

A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)

NCT06526923Cystic Fibrosis

Spirovant Sciences, Inc.

Phase 1/2

Kansas, Massachusetts, New York, Pennsylvania

2024-09-16

Active, closed

A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma

NCT06550895Multiple Myeloma

DrugsCilta-cel·Talquetamab

Janssen Research & Development, LLC

Phase 2

Iowa, Kentucky, Michigan, New York, Pennsylvania

2024-09-16

Recruiting

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

NCT06140524Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM)

DrugLinvoseltamab

Regeneron Pharmaceuticals

Phase 2

116

Maryland, Massachusetts, Michigan, New York, Pennsylvania, Washington

2024-09-16

Recruiting

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

NCT06567743High-Risk Non-Muscle-Invasive Bladder Cancer

DrugCretostimogene Grenadenorepvec

CG Oncology, Inc.

Phase 2

325

Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana

2024-09-16

Recruiting

Application of the Belle.AI Dermatological Image Reference System for Patient Diagnosis in an Active Clinical Setting

NCT06724627Skin Condition, Dermatology, Dermatology/Skin - Other

BelleTorus Corporation

Not applicable

263

New York

2024-09-16

Not yet open

The VIS Opti-K Low Vision Aid Device Provides Vision Improvement.

NCT06597292Hyperopia, Presbyopia

VIS, Inc.

Not applicable

200

Texas

2024-09-16

Recruiting

A Study of VET3-TGI in Patients With Solid Tumors

NCT06444815Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer

DrugAtezolizumab

KaliVir Immunotherapeutics

Phase 1

California, Florida, Indiana, Pennsylvania, Texas

2024-09-16

Recruiting

Safety and Effectiveness of eGERD Device to Reduce Gastroesophageal Reflux Disease (GERD) Symptoms

NCT06613438GERD (Gastroesophageal Reflux Disease)

Gerd Care Medical Ltd

Not applicable

Illinois

2024-09-15

Recruiting

Use of the Neurolyser XR for the Treatment of Low Back Pain Related to Sacroiliitis

NCT06053255Sacroiliitis

FUSMobile Inc.

Not applicable

Virginia

2024-09-13

Recruiting

A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy

NCT06388707Drug Resistant Epilepsy, Epilepsy, Seizures, Focal, Seizure

NaviFUS Corporation

Phase 1/2

California, Massachusetts, Virginia

2024-09-13

Active, closed

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer

DrugsLeucovorin·Irinotecan·Cetuximab·Adrucil

Eli Lilly and Company

Phase 1

630

California, Colorado, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Michigan

2024-09-12

Active, closed

Safety of the Sonablate HIFU System for the Ablation of Incompetent Veins of the Periphery

NCT06642051Chronic Venous Insufficiency, CVI, Venous Malformations, Venous Leg Ulcers, Klippel-Trenaunay Syndrome

Sonablate

Not applicable

Connecticut

2024-09-11

Recruiting

Bone Mineral Density Agreement Study Between EOSedge™ Versus Traditional DXA

NCT06659055Healthy, Indicated for EOSedge Imaging

Alphatec Spine, Inc.

Not applicable

214

Arizona, California, Tennessee, Virginia

2024-09-11

Recruiting

A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

NCT06572384Lung Diseases, Interstitial

DrugBelimumab

GlaxoSmithKline

Phase 3

440

California, Florida, Missouri, New York, North Carolina, Pennsylvania, Texas, Utah

2024-09-11

Recruiting

The TRICURE EFS Study

NCT06506942Tricuspid Valve Regurgitation, Heart Valve Diseases, Cardiovascular Diseases

TRiCares

Not applicable

Georgia, Illinois, Michigan, Minnesota, New York, Ohio, South Carolina

2024-09-11

Recruiting

AVAVA MIRIA General Use

NCT06868615Acne, Acne Scars - Mixed Atrophic and Hypertrophic, Scars, Wrinkle

AVAVA, Inc.

Not applicable

200

Massachusetts

2024-09-11

Recruiting

Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

NCT06423430Treatment Resistant Depression

Abbott Medical Devices

Not applicable

100

Alabama, California, Florida, Georgia, Illinois, Indiana, Massachusetts, Minnesota

2024-09-11

Recruiting

A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

NCT06559150Non-cystic Fibrosis Bronchiectasis

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA

Phase 2

284

Alabama, California, Colorado, District of Columbia, Florida, Georgia, Indiana, Iowa

2024-09-11

Active, closed

A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

NCT06431373Uveitis, Posterior, Uveitis, Intermediate, Uveitis

Priovant Therapeutics, Inc.

Phase 3

371

Arizona, California, Colorado, Florida, Illinois, Indiana, Kansas, Maryland

2024-09-11

Active, closed

ABA-101 in Participants With Progressive Multiple Sclerosis

NCT06566261Progressive Multiple Sclerosis

Abata Therapeutics

Phase 1

Maryland, New Jersey, Ohio

2024-09-11

Active, closed

Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction

NCT05839730Heart Failure With Preserved Ejection Fraction, Concentric Hypertrophy

Medtronic Cardiac Rhythm and Heart Failure

Not applicable

105

Florida, Illinois, Kansas, North Carolina, Oklahoma, Texas, Vermont

2024-09-11

Recruiting

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

NCT06379789Hemophilia B

Regeneron Pharmaceuticals

Phase 1/2

130

Arizona, California, Colorado, Connecticut, Florida, Indiana, Louisiana, Michigan

2024-09-11

Active, closed

Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome

NCT06315751Tourette Syndrome

Noema Pharma AG

Phase 2

164

Arizona, California, Florida, Georgia, Massachusetts, Michigan, Missouri, Nebraska

2024-09-10

Active, closed

A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)

NCT06817343Neovascular Age-Related Macular Degeneration (nAMD), Neovascular (Wet) Age-related Macular Degeneration (AMD)

DrugAflibercept

Exegenesis Bio

Phase 1

Nevada, Pennsylvania

2024-09-10

Active, closed

Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

NCT06417775Migraine

DrugUbrogepant

AbbVie

Phase 3

496

Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Hawaii

2024-09-10

Recruiting

A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

NCT06585241SARS-CoV-2

ModernaTX, Inc.

Phase 4

1,144

Georgia, Louisiana, Mississippi, Nebraska, Virginia

2024-09-09

Recruiting

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

NCT06525298Advanced Solid Tumor, Homologous Recombination Deficiency, HRR Deficiency

DrugsTrastuzumab deruxtecan·Olaparib

Eisbach Bio GmbH

Phase 1/2

144

Texas

2024-09-09

Recruiting

RevCore for In Stent Thrombosis

NCT06394739In-stent Thrombosis

Inari Medical

Observational

100

Connecticut, District of Columbia, Idaho, Maryland, New York, North Carolina, Ohio, Pennsylvania

2024-09-09

Recruiting

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

NCT06246916Melanoma

DrugsFianlimab·Relatlimab·Cemiplimab·Nivolumab

Regeneron Pharmaceuticals

Phase 3

560

Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho

2024-09-09

Active, closed

Safety and Efficacy of Matrix Pro for Eyebrow Lift and Lift of Submental/Neck Laxity

NCT06640998Laxity; Skin

Candela Corporation

Not applicable

150

Massachusetts

2024-09-09

Recruiting

Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA Funnel Catheter

NCT06370182Acute Ischemic Stroke From Large Vessel Occlusion

Anaconda Biomed S.L.

Not applicable

327

Florida, Georgia, Illinois, Iowa, Massachusetts, New York, Oregon, Pennsylvania

2024-09-09

Recruiting

Autologous Hair Follicle Derived Secretome as Adjunct to Aesthetic Procedures

NCT06477172Post Procedural Erythema

Acorn Biolabs Inc.

Observational

500

Alabama, Arizona, California, Colorado, Florida, Illinois, Indiana, Michigan

2024-09-09

Recruiting

Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies

NCT06652633Hematological Malignancies

Lakefront Biotherapeutics NV

Phase 3

546

Massachusetts

2024-09-09

Active, closed

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

NCT06311721Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

DrugsABP 234·Keytruda·Pembrolizumab

Amgen

Phase 3

315

California, Florida, Illinois, Iowa, Michigan, New York, Ohio, Texas

2024-09-09

Active, closed

A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women With an Ovarian Mass

NCT06566716Ovarian Neoplasms

Cleo Diagnostics Ltd

Observational

1,000

Arizona, Florida, Illinois, Massachusetts, Nevada, New York, North Carolina, Ohio

2024-09-06

Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

NCT06476808High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC), Non-small Cell Lung Cancer (NSCLC)

Bristol-Myers Squibb

Phase 1

240

California, New Jersey, Ohio, Texas

2024-09-06

Active, closed

A Study of LY3537031 in Overweight, Obese, and Healthy Participants

NCT06606106Overweight, Obesity

DrugBrenipatide

Eli Lilly and Company

Phase 1

302

California, Florida, Missouri, Texas

2024-09-05

Recruiting

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

NCT06393738Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)

DrugGlofitamab

Arvinas Inc.

Phase 1

329

Connecticut, Florida, Michigan, New Jersey, New York, Ohio, Tennessee, Texas

2024-09-05

Active, closed

Amplitude Vascular Systems (AVS) Lithotripsy POWER PAD 2 Trial

NCT06457685Peripheral Arterial Disease (PAD)

Amplitude Vascular Systems, Inc.

Not applicable

115

Arkansas, California, Colorado, Georgia, Iowa, Missouri, New Jersey, New York

2024-09-05

Active, closed

Study of TTX-MC138 in Subjects With Advanced Solid Tumors

NCT06260774Advanced Solid Tumor

TransCode Therapeutics

Phase 1/2

Texas, Utah, Virginia

2024-09-05

Active, closed

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

NCT06550076Plaque Psoriasis

DrugZasocitinib

Takeda

Phase 3

2,099

Alabama, Arizona, Arkansas, California, Florida, Georgia, Idaho, Illinois

2024-09-04

Active, closed

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

NCT06581198Lupus Erythematosus, Systemic, Lupus Nephritis

DrugRapcabtagene autoleucel

Novartis Pharmaceuticals

Phase 2

179

Alabama, California, Illinois, Iowa, Kentucky, Massachusetts, Missouri, North Carolina

2024-09-04

Active, closed

The SpeedPlate™ Rapid Compression Implant Study (The SPRINT™ Study)

NCT06548581Joint Arthrodesis, Joint Fixation

Treace Medical Concepts, Inc.

Observational

Alabama, Florida, Missouri, Ohio, Texas

2024-09-04

Recruiting

Knee Biofeedback Rehabilitation Through Game Therapy

NCT06090097Knee Osteoarthritis

Barron Associates, Inc.

Not applicable

North Carolina

2024-09-04

Active, closed

A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)

NCT06616974Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction

Tectonic Therapeutic

Phase 2

191

Arizona, California, Colorado, Florida, Georgia, Idaho, Kentucky, Maryland

2024-09-04

Recruiting

Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.

NCT06482905High-grade Glioma, WHO Grade Ⅳ Glioma

Tcelltech Inc.

Phase 1

Arizona, Florida, Minnesota

2024-09-04

Recruiting

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

NCT06548542Crohn's Disease

DrugsTrosunilimab·Lutikizumab·Risankizumab

AbbVie

Phase 2

590

Alabama, California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois

2024-09-04

Recruiting

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

NCT06274801Pulmonary Arterial Hypertension

Gossamer Bio USA, Inc.

Phase 3

330

California, Florida, Georgia, Illinois, Kansas, Kentucky, Michigan, Missouri

2024-09-03

Recruiting

First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors

NCT06554795Solid Tumor, Adult

DualityBio Inc.

Phase 1/2

360

California, District of Columbia, Florida, Illinois, North Carolina, Pennsylvania, Tennessee, Utah

2024-09-03

Recruiting

ATLAS (AltaValve) Pivotal Trial

NCT06465745Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Incompetence, Mitral Valve Regurgitation

4C Medical Technologies, Inc.

Not applicable

450

Arizona, California, Florida, Georgia, Louisiana, Maryland, Massachusetts, Michigan

2024-09-03

Active, closed

A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity

NCT06577766Obesity, Overweight

Novo Nordisk A/S

Phase 1

Kansas, Texas, Utah

2024-09-03

Active, closed

A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma

NCT06381141Multiple Myeloma

DrugCLN-619

Cullinan Therapeutics Inc.

Phase 1

Arizona, Florida, Minnesota, New York, North Carolina, Texas

2024-09-03

Recruiting

PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm

NCT06445608Coronary Artery Disease

Kardion Inc

Not applicable

310

Arizona, Arkansas, Colorado, Connecticut, Florida, Georgia, Indiana, Massachusetts

2024-09-03

Recruiting

A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants

NCT06576271Systemic Lupus Erythematosus

DrugBelimumab

GlaxoSmithKline

Phase 1

142

Arizona, Colorado, Nevada, Ohio, Oklahoma, Texas

2024-09-02

Recruiting

Behavioral AI to Predict and Increase Peritoneal Dialysis Uptake

NCT06533254Chronic Kidney Disease

Scaled Insights

Observational

3,000

Texas

2024-09-01

Recruiting

NeuroTrainer Cognitive Training For Academic Focus

NCT06512974ADHD - Combined Type, ADHD Predominantly Inattentive Type, ADHD, Predominantly Hyperactive - Impulsive

NeuroTrainer

Not applicable

155

Michigan, Nebraska, Wisconsin

2024-09-01

Active, closed

Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide

NCT06484114Obesity, Weight Change Trajectory, Weight Change, Body

Fractyl Health Inc.

Not applicable

315

Arizona, California, Florida, Indiana, Michigan, New Hampshire, New York, Pennsylvania

2024-09-01

Recruiting

Evaluation of Safety and Effectiveness of Primary Hybrid Construct of Mobi-C and ACDF in the Treatment of Two-level Symptomatic Degenerative Disc Disease in the Cervical Spine.

NCT06485206Degenerative Disc Disease

Highridge Medical

Not applicable

California, Michigan

2024-09-01

Not yet open

Preterm Infants Fed a Human Milk Fortifier

NCT05551975Growth

Abbott Nutrition

Not applicable

321

Arizona, Arkansas, Connecticut, Florida, Massachusetts, Missouri, New Mexico, New York

2024-09

Recruiting

Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease

NCT06343792Steroid Refractory GVHD

DrugRLS-0071

ReAlta Life Sciences, Inc.

Phase 2

California, Georgia, Missouri, Ohio

2024-08-31

Active, closed

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

NCT06116136MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer

DrugsS095029·Keytruda·Pembrolizumab

Servier Bio-Innovation LLC

Phase 1/2

Florida, Indiana, Texas

2024-08-31

Active, closed

Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

NCT06564142Immunoglobulin A Nephropathy

DrugPovetacicept

Alpine Immune Sciences Inc, A Subsidiary of Vertex

Phase 3

605

Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Idaho

2024-08-30

Active, closed

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

NCT06531824Kidney Disease, Chronic

DrugsVicadrostat·Dapagliflozin

Boehringer Ingelheim

Phase 3

8,371

Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois

2024-08-30

Recruiting

Study With [225Ac]Ac-FL-020 in mCRPC Participants

NCT06492122Metastatic Castration-resistant Prostate Cancer

DrugBlood samples for PK

Full-Life Technologies UK Limited

Phase 1

California, Ohio, Virginia

2024-08-30

Recruiting

A Study of Bleeding and Treatment in Participants With Von Willebrand Disease

NCT06610201Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3

Hemab ApS

Observational

200

Arizona, Arkansas, California, Florida, Georgia, Indiana, Louisiana, Michigan

2024-08-30

Active, closed

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

NCT06425302Lymphoma, Follicular

DrugsEndoxan·Golcadomide·Pegylated liposomal doxorubicin·Bendamustine

Celgene

Phase 2

Alabama, Alaska, Arizona, California, District of Columbia, Florida, Kansas, Minnesota

2024-08-30

Active, closed

A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)

NCT06503731Antibody-mediated Rejection

argenx

Phase 2

Alabama, California, Illinois, Nebraska, North Carolina, Ohio, Virginia, Washington

2024-08-30

Active, closed

LMN-201 for Prevention of C. Difficile Infection Recurrence

NCT05330182Clostridioides Difficile Infection

Lumen Bioscience, Inc.

Phase 2/3

375

California, Connecticut, Florida, Illinois, Kentucky, Michigan, Minnesota, New York

2024-08-29

Active, closed

A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease

NCT06557772Coeliac Disease, Celiac Disease

DrugAmlitelimab

Sanofi

Phase 2

229

Arizona, California, Colorado, Florida, Idaho, Kansas, Massachusetts, Michigan

2024-08-29

Recruiting

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

NCT06582017Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma

Nammi Therapeutics Inc

Phase 1

100

California, Colorado, Georgia, New York, Texas, Wisconsin

2024-08-28

Recruiting

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06452277Advanced Non-small Cell Lung Cancer, HER2 Mutation

DrugsSevabertinib·Pemetrexed·Cisplatin·Carboplatin

Bayer

Phase 3

444

California, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan, Minnesota

2024-08-28

Active, closed

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

NCT06486441Endometrial Cancer

DrugsAdriamycin·Sacituzumab Govitecan·Taxol·Doxorubicin

Gilead Sciences

Phase 3

640

Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana

2024-08-28

Active, closed

Phase IIa Study Evaluating AZD7798 in Crohn's Disease

NCT06450197Moderate to Severe Crohn's Disease

DrugAZD7798

AstraZeneca

Phase 2

120

Arizona, California, Florida, Idaho, Kansas, Michigan, Missouri, North Carolina

2024-08-28

Recruiting

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

NCT06193889Myasthenia Gravis, Generalized Myasthenia Gravis

DrugsKYV-101·Fludarabine·Cyclophosphamide

Kyverna Therapeutics

Phase 2/3

California, Florida, Indiana, Missouri, Oregon, Pennsylvania, Texas, Utah

2024-08-28

Recruiting

First In Human Study of CX-801 in Advanced Solid Tumors

NCT06462794Solid Tumor, Adult

DrugsKeytruda·Pembrolizumab

CytomX Therapeutics

Phase 1

121

California, Colorado, Pennsylvania, Tennessee, Texas

2024-08-28

Recruiting

Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)

NCT06562907Weight Management

DrugOmeprazole

Gilead Sciences

Phase 1

134

Florida, Texas, Utah

2024-08-28

Active, closed

Volrustomig Priming Regimens Exploratory Phase II Platform Study

NCT06448754Non-small Cell Lung Cancer

DrugsVolrustomig·Ramucirumab·Pemetrexed·Paclitaxel

AstraZeneca

Phase 2

194

California, North Carolina

2024-08-27

Active, closed

Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)

NCT06460844Retinitis Pigmentosa, Choroideremia

Ray Therapeutics, Inc.

Phase 1

California, Pennsylvania, Texas

2024-08-27

Active, closed

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)

NCT06625411Thyroid Eye Disease

DrugVRDN-003

Viridian Therapeutics, Inc.

Phase 3

132

Arizona, California, Florida, Georgia, Illinois, Massachusetts, Michigan, Missouri

2024-08-27

Active, closed

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)

NCT06625398Thyroid Eye Disease

DrugVRDN-003

Viridian Therapeutics, Inc.

Phase 3

204

Arizona, California, Florida, Georgia, Illinois, Massachusetts, Michigan, Missouri

2024-08-27

Recruiting

A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease

NCT06565195Parkinson's Disease

Prevail Therapeutics

Phase 1

124

Colorado, Connecticut, Florida, Illinois, Michigan, Pennsylvania, Texas

2024-08-27

Active, closed

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

NCT06449222Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers

DrugsEribulin·Pumitamig·Gemcitabine·Paclitaxel

BioNTech SE

Phase 2

California, Colorado, Connecticut, Illinois, Minnesota, New Jersey, New York, Tennessee

2024-08-26

Recruiting

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

NCT06500884Multiple Myeloma

DrugsRamantamig·Talquetamab

Janssen Research & Development, LLC

Phase 2

210

California, Colorado, Connecticut, New York, North Carolina, Ohio, Virginia, Washington

2024-08-26

Active, closed

A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

NCT06564311Relapsing Multiple Sclerosis

DrugObexelimab

Zenas BioPharma (USA), LLC

Phase 2

Alabama, Arizona, California, Florida, Massachusetts, Minnesota, Missouri, New Jersey

2024-08-26

Active, closed

A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their Infants

NCT06126835Ulcerative Colitis

DrugOzanimod

Bristol-Myers Squibb

Observational

2,828

Minnesota

2024-08-26

Active, closed

Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

NCT06572228Asthma

DrugsIcs-Laba·Dupilumab

Regeneron Pharmaceuticals

Phase 4

120

California, Colorado, Florida, Idaho, Illinois, Kansas, Kentucky, Maine

2024-08-26

Recruiting

Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

NCT06352359Advanced Solid Tumor

OncoC4, Inc.

Phase 1

California, Florida, Kentucky, Michigan, Pennsylvania, Texas, Utah

2024-08-23

Active, closed

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

NCT06556368Wet Age-related Macular Degeneration

DrugsTabirafusp tedromer·Eylea·Aflibercept

Kodiak Sciences Inc

Phase 3

667

Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana

2024-08-23

Active, closed

Data Collection For Adventitious Lung Sounds Algorithm Using Eko Digital Devices in a Clinical Setting

NCT07360522Lung Diseases

Eko Devices, Inc.

Observational

750

Texas

2024-08-23

Recruiting

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

NCT06362369Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis

DrugsYervoy·Ipilimumab·Opdivo·Nivolumab

7 Hills Pharma, LLC

Phase 1/2

126

Colorado, Florida, New Hampshire, Rhode Island, Texas

2024-08-23

Active, closed

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

NCT06413498Multiple Myeloma

DrugsAnitocabtagene Autoleucel·Carfilzomib·Pomalidomide·Bortezomib

Kite, A Gilead Company

Phase 3

452

Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana

2024-08-23

Recruiting

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)

DrugsVolrustomig·Adrucil·Paclitaxel·Cisplatin

AstraZeneca

Phase 2

257

California, Maryland, New York, Ohio, Pennsylvania

2024-08-22

Recruiting

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

NCT06415487Locally Advanced Solid Tumor, Metastatic Solid Tumor

DrugsFludarabine·Cyclophosphamide·Pembrolizumab

Acepodia Biotech, Inc.

Phase 1

California, Colorado, Tennessee, Texas

2024-08-22

Active, closed

Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo

NCT06577090Obesity

Skye Bioscience, Inc.

Phase 2

136

Alabama, California, Connecticut, Georgia, Kentucky, Nebraska, Nevada, New Hampshire

2024-08-22

Active, closed

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

NCT06533059Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer

Alterome Therapeutics, Inc.

Phase 1

110

California, Colorado, Florida, Massachusetts, Missouri, Tennessee, Texas, Virginia

2024-08-22

Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site. Derived from ClinicalTrials.gov. Retrieved 8 November 2026. https://priyalifescience.com/clinical-trials-usa?page=10

Query this register directly

GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,120 studies in total at the last sync on 08 Nov 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

How many clinical trials are recruiting in the US?

4,955 of the 9,120 studies in this register are recruiting new participants as of the 08 Nov 2026, 03:16 UTC sync. A further 482 have not yet opened recruitment, 3,309 are active but closed to new participants, and 374 are enrolling by invitation only. Eligibility for any study is decided by its study team.

→

Browse trials by condition

Advanced Solid Tumor (143) Obesity (136) Breast Cancer (132) Multiple Myeloma (110) Advanced Solid Tumors (94) Overweight (87) Colorectal Cancer (86) Solid Tumor (83) Ovarian Cancer (78) Heart Failure (72) Prostate Cancer (72) Non-Small Cell Lung Cancer (71) Healthy (68) Cancer (64) Melanoma (60)

→

Browse trials by state

California (5303) Florida (4471) Illinois (2484) Georgia (2362) Arizona (2258) New York (2129) Colorado (2070) Texas (1973) Massachusetts (1840) Michigan (1473) Alabama (1313) Connecticut (1300) Maryland (1257) Ohio (1246) Indiana (1124)

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.